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 Porcine circovirus is the primary causative agent responsible for inducing a group 
of associated diseases known as porcine circovirus associated diseases (PCVAD), which 
can have detrimental effects on production efficiency as well as lead to mortality. The 
variation in host genetics plays a role in the ability to initiate an effective immune 
response. The objective of this research was to identify major genetic variants and genes 
that influence immune response and PCVAD susceptibility. Commercial crossbred pigs 
(n=974) were experimentally infected with a PCV2b strain to analyze genetic sources of 
variation in PCVAD susceptibility. The strain used for experimental infection was 
recovered from a pig that displayed characteristic signs of post-weaning multisystemic 
wasting syndrome (PMWS). To evaluate the variation in response, blood and weights 
were collected from all pigs at days 0, 7, 14, 21, and 28 post infection. Blood samples 
were used to analyze PCV2 specific antibody (IgM and IgG) PCV2b viremia. Pair-wise 
correlations between phenotypic and genomic prediction values were estimated to 
evaluate common sources of variation. In addition, a genome-wide association study 
(GWAS) including 56,433 SNPs was performed to analyze the genomic regions 
 
 
responsible for the variation in host susceptibility to PCV2. The GWAS identified two 
important SNPs responsible for explaining approximately 11.5% (ALGA0110477; SSC 
12) and 2.8% (ALGA0039710; SSC 7) of the genetic variation observed for viral load. 
Negative correlations between average daily gain (ADG) and viral load during the 
experimental challenge (r= -0.36, P<0.0001). Pigs exhibiting the CC genotype for the 
ALGA0110477 SNP demonstrated lower viral load (P< 0.0001) and higher overall ADG 
(P< 0.05) compared to the CT and TT genotypes. These genetic variants influence the 
host’s ability to stimulate immune response, and can therefore be utilized for selection to 
reduce PCV2b susceptibility. Selection based on these DNA markers can improve 
general animal health and welfare, provide an alternative to vaccinations, and decrease 
production costs.  
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INTRODUCTION 
 
 The first discovery of porcine circoviruses (PCV) occurred in 1974, when Tischer 
and others discovered a contaminant of porcine kidney cell lines PK-15 (ATCC-CCL31) 
(Tischer et al., 1974); however, it wasn’t until 1982 when the first true description of the 
agent was given (Tischer et al., 1982). 
Porcine circoviruses (PCV) are small, non-enveloped, icosahedrical, DNA viruses 
(Lukert et al., 1995) that are classified within the Circoviridae family and Circovirus 
genus (Meng X. J., 2013a). PCV are one of the smallest classifications of DNA viruses 
capable of infecting and replicating in mammalian cells (Kim et al., 2004b). The most 
notable PCV is porcine circovirus type 2 (PCV2), which is an economically important 
pathogen because it has the capability to infect large populations due to its infectious 
proficiency.  PCV2 is the etiological agent responsible for inducing the development of 
porcine circovirus associated diseases (PCVAD), which is a multifactorial disease that 
impacts production efficiency and increases mortality rates (Opriessnig et al., 2006a). 
PCV2 contains a circular, single-stranded DNA genome that consists of 1768 nucleotides 
(Gillespie et al., 2009), and PCV2 uses three open reading frames (ORF) for replication 
(Meng, 2013a). ORF1 encodes for non-structural, replicase proteins that facilitates viral 
replication. ORF2 encodes for capsid proteins (Cap) to protect the viral DNA (Hamel et 
al., 1998; Mankertz et al., 1998; Nawagitgul et al., 2000; Carman et al., 2008). The 
function of ORF3 is not entirely understood, but it has been suggested that it encodes a 
non-structural protein involved with apoptosis in vitro and viral pathogenesis in vivo (Liu 
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et al., 2006) and that it plays a role in the systemic spread of infection by recruiting 
macrophages (Karuppannan et al., 2011). 
 PCV2 is divided into two sub-categories consisting of PCV2a and PCV2b. PCV2a 
was first identified in North America and PCV2b was first identified in Europe (Takahagi 
et al., 2009). Previous research has established that PCV2b is more virulent than PCV2a, 
and is the major causative agent of PCVAD. 
  The major signs characterized by PCV2 infections include weight loss, skin 
discoloration, respiratory signs, diarrhea, interstitial pneumonia, nephritis, reproductive, 
dermatitis as well as lymphoid depletion (Harding and Clark, 1997; Krakowa et al., 
2002). Although the pathogenesis of the virus is not fully understood, it has been 
suggested that the virus invades macrophages and dendritic cells, which causes 
immunosuppression (Opriessnig et al., 2007). PCV2 is the contributing factor in PCVAD 
development, which includes several diseases such as post-weaning multisystemic 
wasting syndrome (PMWS), porcine reproductive failure, porcine respiratory disease 
complex (PRDC), and porcine dermatitis and nephropathy (PDNS). PCVAD progression 
is dependent on several factors including PCV2 isolate, presence of co-infections, and 
age at infection.  
 Previous research has indicated host factors such as level of maternal antibodies 
and host genetics play a role in the variation in PCVAD response in several breeds of 
pigs such as Landrace, Large White, Duroc, and Pietrain (Zhou et al., 2006; Opriessnig et 
al., 2006a; Opriessnig et al., 2009b; Bates et al., 2009). For instance, numerous reports 
have indicated that Landrace pigs have increased vulnerability to PCV2 infections 
compared to Large White, Yorkshire, Duroc and Pietrain pigs (Zhou et al., 2006; 
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Opriessnig et al., 2006a). Although research has demonstrated that PCV2 vaccinations 
have an effect on ADG, mortality rates, viremia, shedding and the overall occurrences of 
PCVAD, they increase production costs. In order to prevent outbreaks, every pig in the 
operation has to be vaccinated, which also increases labor and stress to the animals. 
Selection for less susceptible animals could be an alternative to vaccinations as well as 
complementary tool for extra protection in swine operations that experience high 
pathogen exposure. Eventually the use of selection could be implemented into common 
swine management practices to increase pathogen prevention and control. 
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CHAPTER 1 
LITERATURE REVIEW 
 
PCV2 History and Origin 
 Although porcine circovirus type 2 (PCV2) has become a prevailing pathogen in 
the global swine industry, the history and origin of the virus is fairly recent. The earliest 
documented evidence of PCV2 infection in pigs was detected using in situ hybridization 
and polymerase chain reaction in tissue samples from 1962 in pigs that originated from 
Northern Germany (Jacobsen et al., 2009). In 1974, Tischer initially discovered a 
contaminant of the porcine kidney cell lines PK-15 (ATCC-CCL31), which was 
described as a picornavirus-like virus (Tischer et al., 1974). It wasn’t until 1982, when 
Tischer gave the first true description of the contaminant agent as a circular single 
stranded DNA virus, which was eventually named Porcine Circovirus (PCV), and today 
is known as PCV type 1 (Tischer et al., 1982).  
 In a study involving an experimental infection of PCV, Tischer et al. (1986) 
demonstrated that the virus did not elicit clinical disease, nor where there detectable sites 
of viral replication. Serological examinations performed on blood samples collected in 
the experimental population did reveal the presence of PCV antibodies; however, no 
clinical disease could be attributed to the PK-15 (ATCC-CCL31) isolate and was 
therefore considered to be non-pathogenic (Allan et al., 1994; Dulac and Afshar 1989; 
Tischer et al., 1986).  
 In 1995, Allan et al., confirmed these results and demonstrated that infecting 
Cesarean-delivered and colostrum deprived pigs did not elicit clinical illness, or produce 
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lesions; however viral replication was detected (Allan et al. 1995; Tischer et al. 1986). 
The PCV isolate was eventually assigned to the Circoviridae family (Lukert et al., 1995). 
 Until the early 1990s, the common notion was that PCV was considered to be 
non-pathogenic; however, in 1991, Canadian swine producers began experiencing a 
newly developing disease in high-health herds (Opriessnig et al., 2006a). It was estimated 
that only 2.5% of collected tissues profiled from a large set of animals between 1962 and 
1984 were infected with PCV2; however, in 1985, the prevalence of PCV2 increased 
substantially to over 30% (Trible et al. 2012). 
 This new disease syndrome was characterized by rapid loss of weight, and 
respiratory distress and termed post-weaning multisystemic wasting syndrome (PMWS) 
and was officially reported first in western Canada in 1991 (Clark, 1997; Harding, 1997). 
PMWS is characterized by a variety of clinical signs including wasting in weaned pigs, 
dyspnea, palpable lymphadenopathy, diarrhea, pallor and lymphoid depletion in 
lymphoid tissues (Allan et al., 2000a; Opriessnig et al., 2006a).  
 Later studies revealed an association between PMWS and a new antigenically and 
genomically distinct PCV global swine population (Allan and Ellis, 2000). It was 
proposed that this new circovirus should be designated as PCV type 2  (PCV2) and the 
non-pathogenic contaminant of the porcine kidney cell lines PK-15 should be designated 
PCV type 1 (PCV1)(Allan et al., 1998b; Meehan et al., 1998).  In 1998, the first PCV2 
isolation and characterization of PCV2 isolates occurred as well as the first sequences of 
the complete PCV2 genome became available (Allan et al., 1998a; Ellis et al., 1998; 
Meehan et al., 1998; and Morozov et al., 1998). 
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 PCV2 is also associated with numerous other syndromes including porcine 
dermatitis and nephropathy syndrome (PDNS)(Rosell et al., 2000), porcine respiratory 
disease complex (PRDC), sporadic reproductive failure (West et al., 1999), and porcine 
respiratory-disease complex in North America (Harms et al., 2002; Opriessnig et al., 
2004b). In order to group all of the diseases and syndromes associated with PCV2, the 
term porcine circovirus associated diseases (PCVAD) was proposed in 2002 by the 
American Association of Swine Veterinarians (AASV) to collectively name conditions 
triggered by the same pathogen (Allan et al., 2002). 
 
Taxonomy  
 Both types of the porcine circovirus are classified in the genus Circovirus, which 
is within the Circoviridae family (Meng X. J., 2013a) and are known to infect birds and 
pigs (Linlin et al., 2010). The genomic organization as well as the replication approach of 
circoviruses is analogous with members of plant geminiviruses and nanoviruses (Meng 
X. J., 2013a). Currently there are at least 11 species of circoviruses including PCV1 and 
PCV2 and numerous avian circoviruses (Meng X. J. 2013b) including beak and feather 
disease virus (Ritchie et al., 1989), pigeon circovirus (Woods et al., 1993), canary 
circovirus (Phenix et al., 2001), goose circovirus (Todd et al., 2001), duck circovirus 
(Hatterman et al., 2003, finch circovirus (Shivaprasad et al., 2004) and gull circovirus 
(Smyth et al, 2006). 
 Members of the Circoviridae family consist of small, icosahedrical, single-
stranded DNA (ssDNA) viruses that infect vertebrates (Lukert et al., 1995).  Porcine 
circoviruses are one of the smallest DNA viruses that are capable of infecting mammals 
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and replicating independently in mammalian cells (Kim et al., 2004b). Circoviruses have 
circular genomes and range in size from 1.8 to 2.3 kilobases (Opriessnig et al., 2007).  
 In addition, circoviruses are non-enveloped also known as naked viruses, which 
consist of nucleic acid (DNA) and a protein capsid to protect the viral genome. The 
nucleocapsids of naked viruses attach themselves to the target cells of the host; where as 
enveloped viruses fuse their envelope with host membranes. Using disinfectants to 
eliminate circoviruses is difficult because circoviruses are non-enveloped viruses, which 
makes them resistant to various sterilizers such as those with alcohol, chlorhexidine, 
iodine, and phenol bases (Grau-Roma et al., 2011). 
 
Porcine Circovirus Characteristics 
 Porcine circoviruses are among the smallest animal viruses with a virion particle 
diameter of 17±1.3 nm (Tischer et al., 1982) consisting of a circular, negative sense, 
single stranded genome approximately 1.7kb (Chae, 2005; Meng, 2013b). The 
icosahedral virion contains 60 capsid protein subunits, which are arranged in 12 flat 
pentamer clustered units (Crowther et al., 2003; Khayat et al., 2001). 
 Porcine Circoviruses are broken up into type 1, which is considered to be non-
pathogenic and type 2, which is pathogenic. Currently research involving porcine 
circoviruses is primarily focused on type 2 because it has been shown to produce clinical 
illness and contributes to several diseases (Finsterbusch and Mankertz, 2009). Although 
they differ in virulence, porcine circovirus type 1 and type 2 share about 75% nucleotide 
sequence identity (Opriessnig et al., 2006b).  
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 Porcine circovirus genomes have slightly varying genomes. For instance PCV1 
isolates range from 1,758 to 1,760 base pairs, while PCV2 isolates range from 1,767 to 
1,768 base pairs (Allan et al., 1998b; Hamel et al., 1998; Meehan et al., 1998; Morozov et 
al., 1998; Fenaux et al., 2000; Opreissnig et al., 2006b; Huang et al., 2011). Nucleotide 
sequence identity between the PCV1 isolates as well as between the PCV2 isolates is 
greater than 90% (Hamel et al., 1998; Meehan et al., 1998; Morozov et al., 1998; Cheung 
and Bolin, 2002). 
 
Porcine Circovirus Genomic Organization 
 PCV1 and PCV2 have similar genomic organization, consisting of 11 potential 
ORFs (Hamel et al., 1998). To enhance efficiency, the genomic organization of PCVs is 
reduced to absolute necessities to achieve the two basic functions of a virus, which is to 
copy and package the viral genome (Meng, 2013a). Therefore, porcine circoviruses rely 
on three major open reading frames (ORFs) to replicate. 
 For instance, ORF1, which is located on the positive strand of the genome and is 
positioned in the clockwise direction, facilitates viral replication. ORF1 encodes for non-
structural, viral replicase proteins Rep (35.7 kDa) and a frame-shifted variant Rep’ (20 
kDa), which has been alternatively spliced (Mankertz et al., 1998; Mankertz and 
Hillenbrand, 2001;Mankertz et al., 2003). Both of these proteins are involved in viral 
replication; however, sequence size varies slightly between PCV1 and PCV2. For 
example, PCV1 Rep and Rep’ contain 312 and 168 amino acids, while PCV2 Rep and 
Rep’ contain 314 and 178 amino acids (Hamel et al., 1998).  ORF1 is the most conserved 
reading frame between PCV1 and PCV2 having 83% nucleotide identity and 86% amino 
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acid identity (Meehan et al., 1998; Morozov et al., 1998). Mutations in either the Rep or 
Rep’ replicase proteins can cause a 99% decrease in viral protein synthesis, which 
terminates viral DNA replication (Cheung et al., 2003). 
 In addition, ORF2, which is located on the negative strand of the genome and is 
positioned in the counter-clockwise direction encodes for viral capsid proteins (Cap) to 
protect the viral DNA (Hamel et al., 1998; Meehan et al., 1998; Morozov et al., 1998; 
Mankertz et al., 1998; Nawagitgul et al., 2000; Carman et al., 2008).  PCV1 Cap protein 
contains 230-233 amino acids, while PCV2 Cap protein contains 233-236 amino acids 
(Hamel et al., 1998; Nawagitgul et al., 2000; Lefebvre et al., 2008; Lefebvre et al., 2009; 
Huang et al., 2011). ORF2 is less conserved between PCV1 and PCV2 compared to 
ORF1. For instance, PCV1 and PCV2 share 67% nucleotide identity and 65% amino acid 
sequence identity (Hamel et al., 1998; Meehan et al., 1998; Morozov et al., 1998; Fenaux 
et al., 2000).  Because Cap is the most variable protein in the PCV genome, it has been 
proposed that there might be an association between the varying Cap proteins and the 
level of pathogenicity of PCV2 (Larochelle et al., 2002). 
 ORF3 is located on the complementary strand in a counter-clockwise position. 
The entire reading frame of ORF3 overlaps ORF1 (Hamel et al., 1998; Meehan et al., 
1998; Morozov et al., 1998).  ORF3 encodes a non-structural protein that in PCV1 
contains 206 amino acids (23.2 kDa) and in PCV2 contains 104 amino acids (11.9 kDa). 
Between PCV1 and PCV2, ORF3 proteins share 62% identity (Hamel et al., 1998; 
Meehan et al., 1998). ORF3 is involved with apoptosis in vitro and viral pathogenesis in 
vivo (Liu et al., 2006); however these results have not been replicated as explained in a 
review by Juhan et al., 2010. In addition, OFR3 has also suggested participation in the 
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systemic spread of the infection by facilitating the recruitment of macrophages for 
infection (Karuppannan et al., 2011). Recent research in both mice (Karuppannan et al., 
2009) and pigs (Juhan et al., 2010) has demonstrated that mutations in ORF3 resulted in 
decreases in PCV2 viremia; though no differences in gross or microscopic lesions were 
detected.  
 
Porcine Circovirus Type 1 
 Although PCV1 infections occur worldwide, research and information involving 
pathogenesis has not been well studied because it is considered to be non-pathogenic 
(Allan et al., 1998a; Allan and Ellis, 2000; Fenaux et al., 2000). It is assumed that 
transmission of PCV1 transpires through ingestion and/ or inhalation (Tischer et al., 
1986); however, some research has shown that shedding can also occur in the milk of 
sows, which transmits to newborn pigs through colostrum (Shibata et al., 2006). There 
has been a limited number of experimental PCV1 inoculations performed on 1 day old, 2 
days old, 1 month old, and 9 months old pigs to look at the pathogenesis (Tischer et al., 
1986; Allan et al., 1995). Furthermore, these experimental PCV1 inoculations did not 
elicit clinical illness. (Allan et al., 1995; Krakowa et al., 2000;). 
 PCV1 has been isolated from nasal secretions at 3 days post inoculation (dpi) as 
well as from fecal samples at 14 dpi; however, the inoculation did not initiate disease, or 
any increase in body temperature (Tischer et al., 1986). PCV1 has also been isolated from 
serum and plasma, which indicates that PCV1 is distributed throughout the body through 
infected monocytes in the bloodstream (Allan et al., 1995).  At 3 dpi, PCV1 antigens can 
be detected in nasal mucosa and other various tissue types including liver, spleen, lung, 
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thymus, and bronchial lymph nodes and also small intestine at 5 dpi (Allan et al., 1995).  
The distribution of PCV1 antigens increases significantly at 7 to 9 dpi (Allan et al., 
1995).  PCV1-specific neutralizing antibodies begin to appear at 7 dpi, which causes a 
decrease in PCV1 antigens. The amount of PCV1-specific antibodies rapidly increases 
between 2 to 5 weeks post infection to eliminate the infection. Once the infection is 
cleared, the levels of PCV1-specific antibodies begin to decrease; but are still detectable 
until 39 to 47 weeks post inoculation (Tischer et al., 1986). 
 PCV1 antigens can be detected in various tissue types, but are primarily present in 
cells of the spleen, thymus and lung (Allan et al., 1995). PCV1 antigens are generally 
detected in non-epithelial cell types that are morphological similar to macrophages, 
histiocytes, dendritic cells and other antigen presenting cells; however, primary sites of 
viral replication are still unknown (Allan et al., 1995). 
 
Porcine Circovirus Type 2 
 PCV2 can be divided into three sub-categories based on genomic DNA 
sequencing including PCV2a, PCV2b, and PCV2c. Of these sub-categories, PCV2a and 
PCV2b are the most common and occur worldwide. PCV2a was most commonly 
detected in North America, while the PCV2b was identified in Europe (Takahagi et al., 
2009). Initially, PCV2a was the predominate genotype; however, in 2000 PCV2b entered 
into North America most likely from Europe and spread across the continent, triggering 
high mortality and morbidity. The rapid spread of PCV2b in North America had 
devastating effects in major swine production region. Various studies presented in a 
review article conducted by Grau-Roma et al. (2011) demonstrate that PCV2b is more 
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prevalent in natural infections, which may indicate that PCV2b has a higher virulence and 
is more persistent in the environment compared to PCV2a. In a review paper written by 
Grau-Roma and others in 2011, several studies confirm that PCV2b is the most common 
natural infecting strain. In addition, PCV2b is also considered to be more virulent 
compared to PCV2a, which is associated with non-PMWS-affected farms (Carmen et al., 
2008 and Grau-Roma et al., 2008). 
 Most PCV2 infections predominately occur through the nasal route and are shed 
through nasal, ocular, and oral secretions in addition to milk, urine, semen, and feces 
(Krakowa et al., 2000; Larochelle et al., 2000; Kim et al., 2001; Segalés et al., 2005).  
Furthermore, pigs that are clinically infected will shed PCV2 at a higher rate compared to 
sub-clinically infected pigs (Segalés et al., 2005). 
 One of the most problematic issues involving PCV2 infections is that some pigs 
can remain asymptomatic, which can make diagnosis extremely difficult.  Highly viremic 
pigs may develop any of the diseases associated with PCV2 infections.  
 
Pathogenesis 
 The events leading to initial stages of PCV2 infection and replication are still 
somewhat ambiguous to research scientists; therefore, further research is a necessity to 
make conclusive assumptions. PCV2 is capable of infecting dendritic cells (DC) and 
modulating their activity; however, they show no evidence of replicating in these cells 
(McCullogh et al., 2009). It has been suggested that PCV2 infections seem to cause 
lymphoid depletion and a reduction in levels of lymphocytes in peripheral blood, which 
can lead to reduced bone marrow production, reduced proliferation in secondary 
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lymphoid tissues, and reduced levels of lymphocytes in bone marrow, peripheral blood, 
or secondary lymphoid tissues (Opriessnig et al., 2007). PCV2 can be detected as early as 
7 dpi; however, viral titres peak between 14 and 21 dpi (Rovira et al., 2002; Resendes et 
al., 2004; Opriessnig et al., 2008a).  By the second week of infection, PCV2 can be 
detected in numerous tissue types and several organs, though lymphoid tissues are 
primary sites of infection and typically contain the highest levels of viral load.  
 Although it has been demonstrated that PCV2 establishes itself in both 
macrophages and dendritic cells, previous studies involving in vitro models have 
determined that monocytes are not sites of PCV2 replication (Opriessnig et al., 2007). 
PCV2 infected pigs have demonstrated that the highest levels of PCV2 virions exist in the 
cytoplasm of monocyte/macrophage lineage cells (Rosell et al., 1999; Sanchez et al., 
2004). In addition, in vitro studies have also demonstrated that PCV2 is able to infect 
theses cells and persist; however, without replication (Gilpin et al., 2003; Vincent et al., 
2003). A review by Opriessnig et al., 2007 describes the work of Gilpin et al., 2003, and 
describes that macrophages and monocytes were tested for PCV2 replication, though 
replication was not observed. The PCV2 genome does not code for its own replication 
machinery, such as its own DNA polymerases. Instead, the virus relies entirely on host 
cells that are in the S-phase to complete its infectious cycle (Tischer et al., 1987). 
Because of this, the general assumption is that cells with higher mitotic rates are the most 
efficient in facilitating PCV2 replication. 
 Although monocytes may not be the primary site of PCV2 replication, it has been 
proposed that they might be involved in the mechanism responsible for systemic-spread 
(Vincent et al., 2003). PCV2 is also able to stimulate deficiency of in vitro cultured 
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dendritic cells (DC) (Vincent et al., 2005).  Because dendritic cells can initiate an 
immune response, control lymphocyte homeostasis, and exist in many locations such as 
the skin, mucosal surface, and circulating in blood they are able to respond to viruses 
very quickly. Dendritic cells also encapsulate antigens and travel to lymph nodes and 
organs to initiate T cell activation to increase immune response (Vincent et al., 2003). A 
study conducted in 2003 by Vincent and others, determined that bone marrow derived 
and monocyte-derived dendritic cells were affected by PCV2 infections. Additionally, a 
review conducted by Opriessnig et al., (2007), further described Vincent’s work and 
demonstrated that although PCV2 was able to exist in dendritic cells without initiating 
apoptosis, replication did not occur in dendritic cells.  
 Furthermore, it has been proposed that dendritic cells could be exploited as means 
of transportation because of their capability to move throughout the body. Because 
dendritic cells play a vital role in mediating innate and virus-specific immune response, 
understanding the mechanism of dendritic cell impairment may be critical in clarifying 
the immune events during PCV2 infections. In 2002, Fenaux and others performed a 
cutting-edge study where an infectious clone of PCV2 was developed to examine its role 
in systemic diseases. Specific pathogen-free pigs were injected with the PCV2 clone 
directly into the liver and superficial iliac lymph nodes. PCV2 antigen was detected in 
various tissue types at 35 dpi and lesions were discovered in the lymph nodes as well as 
the lungs. This study is significant in a sense that it proved that transfection could be used 
in vivo to study the associations of PCV2 genes to evaluate their functions in viral 
replication and pathogenesis. 
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 After 14 dpi, specific PCV2 immune responses begin to develop (Pogranichnyy et 
al., 2000; Resendes et al., 2004a; Meerts et al., 2005). It has been proposed that the 
capability to initiate a sufficient adaptive immune response can prevent PCV2 
progression towards PMWS. For instance, the induction of PCV2 antibody development 
is usually followed by a decline in viral titres, which typically results with viral 
dissipation (Resendes et al., 2004a; Meerts et al., 2005; Fort et al., 2007; Opriessnig et 
al., 2008b).  
 Sub-clinically affected pigs that tend to demonstrate lower PCV2 viremia, 
typically experience minimal modifications of the immune system allowing the host to 
recover from the infection.  However, there have been reports of sub-clinically infected 
pigs that demonstrate high antibody titres, long-term viremia as well as detection of 
PCV2 in various tissues (Allan et al., 1999; Pogranichnyy et al., 2000; Resendes et al., 
2004). In addition, a reduction in humoral responses, such as a decrease in neutralizing 
antibodies (NA) (Meerts et al., 2006) is associated with an increase in viral replication. 
Of the PCV2 specific antibodies, IgG is predominantly associated with neutralizing 
capacity (r= 0.85, P< 0.001) (Fort et al., 2007). This results in severe lymphoid lesions 
and major immune system alterations, which could induce an immunosuppressive state, 
leading to PMWS.  
 The cause of why certain pigs develop clinical symptoms, while others do not, is 
not clearly understood; however, a review conducted by Opriessnig and others in 2007 
described several factors that influence PCV2b progression/reduction, such as virus-
dependent factors, host dependent factors, effects of co-infections and immune 
modulation. 
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Virulence 
 There are numerous factors that influence PCV2 pathogenesis and disease 
progression. One of the most important influences is virulence, which varies depending 
on the strain. Certain isolates may induce clinical symptoms further driving PCV2 
disease progression, while other strains may not show any indications of infection.  
 A majority of the U.S. swine herds are infected with PCV2 (Allan and Ellis 2000; 
Opriessnig et al., 2006a) and most pigs will become exposed to PCV2 at some point 
during the growing period (Larochelle et al., 2003; Opriessnig et al., 2006a). Although 
several farms have reported high PCV2 prevalence with high mortality, many other herds 
do not report any evidence of PCV2 clinical symptoms (Larochelle et al., 2003; 
Opriessnig et al., 2006a). Virulence differences in PCV2 isolates could be one potential 
assertion to the differences in PCV2 intensity (Opriessnig et al., 2006a). 
 Opriessnig and others (2006b) carried out a study comparing two different PCV2a 
isolates (PCV2-40895 and PCV2-4838) to evaluate virus sequence differences and to 
determine the difference in the pathogenicity of the PCV2 isolates. The isolates were 
selected based on field cases with and without PCV2-associated lesions (Opriessnig et al., 
2006b). The first strain, PCV2-40895, was isolated from a pig diagnosed with post-
weaning multisystemic wasting syndrome and exhibited lymphoid depletion, high levels 
of PCV2 antigens as well as histiocytic replacement of lymphoid follicles. The second 
strain, PCV2-4838, was isolated from a pig from a herd symptomatic of respiratory 
disease.  In addition, Streptococcus suis, Pasteruella multiocide, and Mycoplasma 
hyopneumoniae were also isolated from this pig. Although PCV2 DNA was detected in 
this pig, no indications of PCV2-associated lymphoid lesions were present. 
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 There were observable differences in several parameters between PCV2-40895 
and PCV2-4838 such as levels of PCV2 in serum and lymphoid tissues and serum 
antibody profiles as well as the severity of PCV2-associated gross and microscopic 
lesions were observed (Opriessnig et al., 2006b). 
 Both PCV2-40895 and PCV2-4838 genomes were sequenced and were each 
found to contain 1768 base pairs.  Between the isolates, there was an overall 98.9% 
nucleotide sequence identity with 20 nucleotide differences. The isolates shared a 99.5% 
nucleotide and 99.4% amino acid sequence identity for ORF1 with 5 nucleotide 
differences. In addition, the isolates shared a 98.0% nucleotide and 96.1% amino acid 
identities with 14 nucleotide differences in the ORF2 capsid gene. In ORF3, the isolates 
shared a 99.0% nucleotide and 99.7% amino acid sequence identities, with one nucleotide 
difference. Although the two PCV2 isolates were genetically similar having an overall 
nucleotide sequence identity of 98.9%, PCV2-4838 was demonstrated to be less virulent 
compared to PCV2-40895, suggesting that different isolates can have varying effects.  
 In another study conducted by Opriessnig and others (2008), 113 pigs were 
inoculated with one of four different PCV2 isolates. The isolates used in this study were 
PCV2-40895 and PCV2-4838 (now known as ISU-40895 and ISU-4838), NC-16845 and 
CAN-17639. The NC-16845 strain was isolated from a pig exhibiting specifically 
lymphadenitis and bronchointerstitial pneumonia. The CAN-17639 strain was isolated 
from a pig exhibiting wasting, coughing, and bronchointerstitial pneumonia. The strains, 
ISU-40895 and ISU-4838 were classified as PCV2a, while NC-16845 and CAN-17639 
were classified as PCV2b. Overall, these four sequences shared a 95.7% nucleotide 
sequence identity, while the PCV2b isolates shared a 99.9% nucleotide sequence identity. 
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Because none of the isolates induced PCV2 clinical symptoms, nor were there any 
differences in macroscopic lesions, this study can only be used to analyze PCV2 
differences between the isolates, and not the differences in their clinical effects. 
 In a study conducted by Grierson and others (2004), 10 PCV2 isolates from the 
Netherlands were examined. Four strains were taken from farms experiencing clinical 
signs of PMWS, and the other six strains were taken from farms with no evidence of 
PMWS. The isolates were sequenced and aligned, demonstrating that the ten strains 
shared between 95.6% and 100% nucleotide sequence identity with 77 nucleotide 
differences. Although the farms presented different levels of clinical symptoms, no 
consistent pattern was observed between the PCV2 isolates from affected and control 
pigs. 
 In similar study in 2004, de Boisseson and others examined isolates from 23 
swine herds in France. A different strain was isolated from each herd.  Ten of the isolates 
did exhibit evidence of PMWS and were classified as PMWS negative, while the other 13 
did demonstrate PMWS symptoms and were classified as PMWS positive.  There was a 
much greater range of nucleotide diversity in the PMWS negative isolates, sharing 94.6% 
to 99.9% nucleotide sequence identity, compared to the PMWS positive isolates, which 
only shared a 99.5% to 99.9% nucleotide sequence identity. In addition, two clusters 
were identified. Isolates from France, the United Kingdom, and the Netherlands were 
categorized into Cluster I, while isolates from North America, Asia, Germany, and Spain 
were categorized as Cluster II. The results from this study reveal that different PCV2 
isolates have varying effects on the progression of PMWS, despite the cluster they belong 
to. For example, some pigs displayed clinical symptoms, while others did not. 
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 Because most of the U.S. swine herds are infected with PCV2 and most pigs will 
likely be exposed to PCV2, with only few a herds experiencing severe mortality and 
morbidity associated with PCV2 infection, it has been suggested that the majority of the 
PCV2 isolates are non-virulent or of low virulence. Therefore understanding the 
molecular basis of virulence of PCV2-associated diseases may aid in developing effective 
vaccines to improve PCV2 diagnosis. 
 
Breed Differences 
 Another significant influence of PCV2 pathogenesis and disease progression is 
host susceptibility.  There have been reports on genetic differences in cattle and poultry 
that influence susceptibility of populations or breeds to parasites, bacteria, and viruses 
(Bumstead et al., 1988; Harmon et al., 1989; Bumstead et al., 1993; and Stear et al., 
1998). In addition, there is evidence for specific breed differences in disease resistance to 
various pathogens including pseudorabies virus (Reiner et al., 2002), PRRSV (Halbur et 
al., 1998a), Escherichia coli (Duchet-Suchaux et al., 1991; Michaels et al., 1994) and 
Sarcocystis miescheriana (Reiner et al., 2002). Although research has demonstrated that 
all pig breeds worldwide are capable of contracting a PCV2 infection, the degree of 
susceptibility differs across breeds. In addition, veterinarians, producers, and pig genetic 
companies have recently shown significant interest in determining if there is a potential 
genetic host component that has a role in influencing PCV2 susceptibility, expression of 
PCVAD and disease progression.  Although successful vaccines have recently become 
available (Fachinger et al., 2008; Fort et al., 2008; Opriessnig et al., 2008b), they increase 
production costs and are labor-intensive. If identified, a DNA marker could possible 
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allow for selective breeding, which might reduce PCVAD occurrence in some swine 
herds. 
 Anecdotal information from veterinarians and producers in the field suggests that 
there are genetic differences within the host effecting susceptibility to PCV2-associated 
diseases Therefore, several studies have been performed to determine if there are breed 
differences in susceptibility to PCV2. For instance, a study conducted by Opriessnig and 
others (2006a) evaluated the difference in susceptibility between three breeds of pigs. 
Seventy-five colostrum-fed, female purebred pigs raised under identical conditions were 
selected from the same farm, which had no evidence of PCV2-associated diseases. The 
experimental pigs consisted of Duroc (=26), Landrace (n=25), and Large White (n=24) 
were inoculated with a single strain of PCV2 (ISU-40895) intranasally and 
intramuscularly at 5 to 7 weeks of age (Opriessnig et al., 2006a). All experimental pigs 
were scored for clinical symptoms, tested serologically and underwent histological 
examination and immunohistochemical analysis. The results form this study 
demonstrated that Landrace pigs had significantly more severe lymphoid depletion in the 
lymph node pool and the tonsil region compared to Duroc and Large White pigs. In 
addition, microscopic lesions characteristic of PMWS were not developed in Duroc and 
Large White pigs, but were identified in 15.8% of Landrace pigs.  Although the there was 
no significant difference in PCV2 susceptibility as indicated by viremia, genomic DNA 
copy counts, and anti-PCV2 antibody levels, there was a difference in the amount of 
lesions characteristic of PMWS in Landrace pigs compared to Duroc and Large White 
pigs. These results indicate that Duroc and Large White pigs are as susceptible to PCV2 
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infections as Landrace pigs; however, Landrace pigs may have a higher vulnerability for 
PCVAD compared to Duroc and Large White pigs. 
 Another study done by Opriessnig and others (2009) was performed to determine 
if possible host genetic differences exist between Landrace and Pietrain breeds under 
experimental conditions. In this study, 78 pigs including 39 Landrace and 39 Pietrain pigs 
were used to evaluate breed susceptibility. The experimental animals were broken up into 
four treatments: Landrace negative control noninoculated (n=13), Landrace PCV2-
infected (n=26), Pietrain negative control noninoculated (n=13), and Pietrain PCV2-
infected (n=26). After passively acquired anti-PCV2 antibodies had declined within the 
selected pigs, the experimental pigs were inoculated with a PCV2 isolate (ISU-40895). At 
21 days post infection (dpi), all of the pigs were necropsied. The results from this study 
suggest that there are some differences between Landrace and Pietrain pigs, which 
contributes to susceptibility to PCV2-associated lesions. From the sampled pigs, the 
Landrace pigs were more susceptible to PCV2-associated lesion and the Pietrain pigs 
were less susceptible to PCV2-associated lesions. The results from this study support 
anecdotal reports from the field.  
 A study conducted by Rose and others in 2005 was done to evaluate an assumed 
Pietrain resistance. This study involved 540 pigs born from three groups of boars: 
Pietrain, and two groups of random boars (Rose et al., 2005). All of the pigs were 
evaluated based on clinical symptoms, and were tested serologically. The overall average 
rate of PMWS manifestation was 18%, and the morbidity rate of random-sired pigs was 
17.3%, while the morbidity rate in Pietrain-sired pigs was 16.3%(Rose et al., 2005). The 
results from this study indicate that Pietrain pigs may possess a genetic component 
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capable of reducing the development of PCVAD. Although these results may suggest 
Pietrain resistance, further research is needed to confirm the assumption of Pietrain 
resistance. 
 
Maternal Antibodies 
 Because piglets are born with low body energy reserves, lack effective immune 
protection, and are exposed to a cold environment and pathogens, they are at risk for 
disease contraction. Therefore, newborn pigs must obtain immune protection as well as 
activate mechanisms responsible for heat production to supply energy to its heat 
producing tissue (Le Dividich et al., 2005). In order to acquire immune protection and 
energy, newborn piglets feed off of the sow first with colostrum and then with milk. 
Through colostrum the sow provides immunity to the offspring, by delivering the 
necessary immunoglobulins to jump-start the pig’s immune system. The antibody 
composition of effective colostrum should contain about 30% IgA, 10% IgM, and 60% 
IgG. These passively acquired antibodies protect against most viral infections to newborn 
piglets (McKeown et al., 2005). 
 A study conducted by McKeown and others (2005) evaluated the role of 
maternally derived antibodies and their effect on reducing the occurrences of PCV2 
infection. In this study, 106 specific-pathogen free piglets free of M. hyopneumoniae and 
porcine reproductive and respiratory syndrome virus (PRRSV) were selected from a 
commercial source. The piglets were selected at 12 days of age and were tested for the 
presence of maternal antibodies by a PCV2-specific enzyme-linked immunosorbent assay 
(ELISA) (Nawagitgul et al., 2002).   From the group of 106 piglets, 24 were selected for 
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the experimental infection based on titres of PCV2 maternal antibodies. The 24 selected 
piglets were categorized based on antibody titres. Group A, consisted of 6 pigs that were 
considered negative for PCV2 maternal antibodies, group B consisted of 5 pigs with low 
PCV2 maternal antibody levels, and both groups C containing 8 piglets, and group D 
containing 5 piglets had high levels of PCV2 maternal antibodies. Groups A, B, and C 
were infected with a PCV2 inoculate at d0, while group D was not infected until d42. 
Pigs from group A experienced seroconversion by 42 days post infection (dpi), which 
indicated the presence of PCV2 infection. Pigs from group B, which had low antibody 
levels, experienced a decline in maternal antibodies by 14 dpi.  By 42 dpi, four of the five 
group B pigs contained PCV2 DNA. In-group C, only two of the eight pigs that 
demonstrated high antibody levels demonstrated PCV2 viremia by 42 dpi. All five group 
D pigs, which were inoculated at d42, were infected with PCV2. All of the pigs were 
challenged again at d42 to determine the length of protection from PCV2 maternal 
antibodies, and to evaluate the result of previous PCV2 exposure on piglets reinfected 
with PCV2.  Of the reinfected groups all were tested negative for maternal antibodies 
except for group C pigs, and only two became viremic. 
 The results of this study indicated that levels of PCV2 maternal antibodies are an 
important element for allowing piglets to mount an immune response to a PCV2 
infection. Furthermore, those piglets with negative or low maternal antibody levels did 
not have sufficient immune protection against PCV2 infection and became viremic, and 
demonstrated seroconversion. This study suggests that there is a potential relationship 
between the levels of PCV2 maternal antibodies, and the degree of immune protection, 
and having a higher level of maternal antibodies results in more immune protection. 
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 Another study conducted by Calsamigilia and others (2007), evaluated the litter 
effect in different PMWS-affected farms and observed the relation to three variables, 
including, sow parity, PCV2 infectious status and sow PCV2 antibody titres. Seven farms 
that demonstrated PMWS in nurseries and/or fattening areas were designated for the 
experiment, and each farm randomly selected 15 sows (105 sows). After farrowing, four 
piglets were selected from each sow (60 piglets per farm; 420 piglets total) and were 
observed for seven months. In addition, pathological exams were performed to inspect for 
symptoms characteristic of PMWS. Of the 420 initial piglets, 104 piglets died (24.8%). 
Of the 104 piglets that died, 40 were diagnosed with PMWS. Thirty-eight of the 105 
(36.2%) sows did not produce any piglets that died during the study period. Of these 
sows, 36 (94.7%) were determined to be PCV2 PCR negative; while 2 out of 7 (28.6%) 
sows that had three or four piglets die during the study period were PCV2 PCR positive. 
Furthermore, 32 of these 38 (84.2%) sows had medium to high antibody titres, where 
only 2 out of 7 (28.6%) sows had medium to high antibody tires. The results of this study 
indicated increasing maternal antibody titres, while decreasing sow infection status could 
reduce PMWS occurrence.  
 The objective in another study, conducted by Opriessnig and others (2004a) was 
to produce PCV2 negative piglets from PCV2 positive sows. Maternal antibody decay, 
transfer of maternal antibodies, and sow herd profiles were examined during the study.  
The piglets produced during this study were not considered viremic.  It was suggested 
that perhaps passively acquired antibodies could inhibit PCV2 replication until levels of 
maternal antibodies decreased; however, after the antibodies had waned, the piglets were 
at risk for PCV2 infection. 
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Co-infections 
 Pigs affected with PMWS can demonstrate a wide range of concomitant 
infections, which can enhance the outcome of PCV2 infection and increase the 
occurrence of PMWS in both experimental and in field conditions (Pogranichniy et al., 
2002; Rose et al., 2003; Dorr et al., 2007).  In natural cases of PMWS, affected pigs 
display a variety of associated infections. In a review conducted by Grau-Roma and 
others (2011), eight viruses, three mycoplasmas, and three bacteria are discussed and 
recognized as co-infecting agents associated with field cases of PMWS. Viral pathogens 
that tend to co-infect with PCV2 include PRRSV, PPV, porcine epidemic diarrhea virus 
(PEDV), Aujeszkys disease virus, Hepatitis E virus, torque teno virus (TTV), porcine 
teschovirus, and swine influenza virus (SIV). PCV2 concomitant mycoplasmas include 
bacterial pathogens that are found in PCV2 infected animal includes Mycoplasma 
hyorhinis, Mycoplasma suis, Mycoplasma hyopneumoniae, Salmonella cholera suis, 
Escherichia coli, and Haemophilus parasuis. Of these co-infecting agents, PPV (Allan et 
al., 1999; Krawkowa et al., 2000), PRRSV (Allan et al., 2000b; Harms et al., 2001) and 
Mycoplasma hyopneumoniae (Opriessnig et al., 2004b) are thought to stimulate PCV2 
associated lesions and increase the occurrence of PMWS. 
 A field study conducted by Pallares and others (2001) examined field cases of 
PMWS from all over North America submitted to a US diagnostic laboratory. The 
objective of the study was to determine the prevalence of different pathogens and identify 
which co-infecting agents are most commonly diagnosed in conjunction with PCV2. In 
this study, 4,688 tissues samples were reviewed for the presence of PCV2 and PMWS. 
Using immunohistochemistry, 1,751 (37%) of the submitted tissue samples, tested 
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positive for PCV2. In addition, 484 (10.3%) of these samples tested positive for PMWS. 
Tissue samples were submitted from North Carolina, Oklahoma, and Minnesota; 
however, about 80% of the samples came from Iowa.   
 The most common concurrent infection was PCV2 and PRRSV with 164 
occurrences, although numerous other combinations of concomitant infections were 
detected as well.  Other infections included PCV2 and Mycoplasma hyopneumoniae (92 
cases), PCV2, PRRSV and Mycoplasma hyopneumoniae (77 cases), PCV2 and bacterial 
septicemia (68 cases), PCV2 and bacterial pneumonia (37 cases) and PCV2 and SIV (13 
cases). From the samples, only nine cases of singular PCV2 were detected. In the cases 
demonstrating PMWS, ages were provided for 369 of the 484 samples. From these 369 
samples, most of the infections occurred between 8 and 18 weeks (294 cases) with the 
most common point of infection occurring at 10 weeks of age.  
 In 2000, a study by Krakowa examined the effects of PCV2 in conjunction with 
PPV in 26 Caesarian derived gnotobiotic piglets. Experimental piglets were divided into 
infection groups as follows: PCV1 singular infection (n=3), PCV2 singular infection 
(n=3), PPV singular infection (n=3), PCV1 and PPV simultaneous infection (n=4), PCV2 
and PPV simultaneous infection (N=4), and PCV1 and PCV2 simultaneous infection 
(n=4), and control piglets (n=3). The results of this experimental infection demonstrated 
that piglets receiving singular infections, and those receiving a simultaneous infection of 
PCV1 and PCV2 remained clinically normal, only exhibiting minimal swelling of lymph 
nodes. The effects of simultaneous infections differed significantly from singular 
infections. All four piglets receiving simultaneous infections of PCV2 and PPV 
developed acute gross lesions characteristic of PMWS, jaundice and subcutaneous edema 
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causing necessary euthanasia on 30 dpi. In addition, three of these four pigs demonstrated 
a decrease in thymus size as well as moderate histological lesions. From the piglets given 
single infectious doses, none of the piglets given PPV and only 50% of piglets given 
PCV1 became viremic. In this study, PCV1 was unable to produce clinical symptoms, 
which confirmed that PCV2 is the primary causative agent responsible for eliciting 
PMWS disease progression and is exacerbated by concurrent infections with other viral 
pathogens. 
 In 2000, Allan and others conducted a study to understand the significance of 
PRRSV infection in the development of PCVAD and explained effects of concurrent 
infections of PCV2 and PRRSV on colostrum-deprived piglets. In this experiment, 3 
treatments were assigned: PRRSV singular infection (n=4), PCV2 singular infection 
(n=3), and PRRSV and PCV2 simultaneous infection (n=5). Pigs given singular 
inoculations did not express clinical and did not develop gross lesions. Of the piglets 
given simultaneous inoculations, one pig suffered enlarged lymph nodes and another pig 
from the same group experienced a decrease in thymic size. In addition, four of the five 
pigs given simultaneous inoculations experienced lymphoid, liver, renal, and vascular 
lesions. From the three infection treatment groups, only pigs given simultaneous 
inoculations expressed clinical illness. The results from this study suggest that PRRSV 
infections can enhance PCV2 replication and stimulate PCVAD disease progression.  
 In a similar study conducted by Harms and others (2001), 59 experimental piglets 
derived from ten different sows were used for experimental infection and challenged with 
PRRSV and PCV2. Experimental piglets were distributed into four treatments as follows: 
control (n=10), singular PCV2 inoculation (n=19), singular PRRSV inoculation (n=13), 
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and concurrent PCV2 and PRRSV inoculations (n=17).  The control pigs did not express 
any clinical respiratory diseases. Before the study started, the singular PCV2 inoculation 
treatment experienced some mortality unrelated to the treatments. One pig from died 
from severe exudative epidermitis, three died from hemorrhagic gastric ulcers, and two 
others were euthanized in the early stage of the study because of jaundice, and 
depression.   Although pigs given a single PRRSV inoculation demonstrated acute 
respiratory problems after 7dpi, no pigs from this group died or were euthanized. Pigs 
given concomitant inoculations of PRRSV and PCV2 demonstrated similar respiratory 
symptoms to PRRSV infected pigs; however, ten pigs contracted severe dyspnea and 
depression between 10 and 20dpi. From this group, four pigs died early and six others 
were euthanized on the terms of animal welfare. The other pigs in this group all died. 
From this study it was observed that pigs given simultaneous inoculations of PRRSV and 
PCV2 experienced more severe hepatic lesions and lymphoid depletion compared to 
single PCV2 infected pigs. Furthermore, all pigs given simultaneous inoculations 
developed necrotizing hepatitis and interstitial pneumonia.  The results of this study are 
similar with other experimental infections involving PCV2 and PRRSV, and again 
suggest that PRRSV plays a role in enhancing PCV2 progression. 
 In another experiment performed by Opriessnig and others in (2004), 67 
experimental pigs were used to investigate the relationship between Mycoplasma 
hyopneumoniae and PCV2.  Pigs were randomly assigned to a treatment groups as 
follows: group 1- controls pigs (n=17), group 2- single M. hyopneumoniae inoculation 
(n=17), group 3- dual inoculation of M. hyopneumoniae and PCV2 (n=17), and group 4- 
single PCV2 inoculation (n=16). Pigs were inoculated at two different time points. At 4 
29 
 
weeks of age, pigs were inoculated intratracheally with M. hyopneumoniae, and 
intranasally with PCV2 at 6 weeks of age. Single M. hyopneumoniae and PCV2 infected 
pigs demonstrated mild to moderate dyspnea, lethargy, and reduced weight gain, where 
pigs given simultaneous M. hyopneumoniae and PCV2 inoculations displayed moderate 
to severe signs of respiratory disease. Similar M. hyopneumoniae associated lesions were 
observed in both single and simultaneous infections. 
 Pigs given dual inoculations and single PCV2 inoculations exhibited severe 
lymph node enlargement; however, pigs given single M. hyopneumoniae inoculations did 
not demonstrate the same circumstance. All of the pigs except for controls developed 
interstitial pneumonia. In addition, four of the 17 simultaneous M. hyopneumoniae and 
PCV2 inoculated pigs developed lesions characteristic of PMWS, though none of the 
singular PCV2 inoculated pigs displayed PMWS symptoms. The results of this study 
indicated that M. hyopneumoniae could play a role in boosting the effects of PCV2 and 
increases PCVAD disease progression. 
 Pogranichniy and others (2002) preformed a field-based case-control study, to 
investigate the role PCV2 and other major swine viral antigens play in the development 
of PMWS. In this study, 31 pigs showing signs of PMWS and 56 controls between the 
ages of 4 and 16 weeks were observed during a 6-month period. All of the pigs were 
tested for numerous viruses including: PCV2, PRRSV, PPV, porcine enterovirus, SIV, 
porcine respiratory coronavirus (PRCV), transmissible gastroenteritis virus (TGEV), 
porcine endogenous retrovirus (PERV), porcine lymphotropic herpesvirus (PLHV) and 
bovine viral diarrhea virus (BVDV). All of the pigs tested positive for PERV, the virus is 
being considered omnipresent in swine. PCV2 was detected in 29 pigs of the 31 PMWS 
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affected field cases (94%) and in 35 of the 56 control pigs (63%). PRRSV was also 
identified in 42% of the PMWS affected field cases and 20% of the control pigs. 
Statistical analysis from this study revealed that an animal infected with PCV2 is 9.3 
times more likely to develop PMWS compared to pigs not infected with PCV2, and an 
animal co-infected with PCV2 and PRRSV is 31.2 times more likely to develop PMWS 
compared to pigs that do not have concurrent infections of PCV2 and PRRSV. The 
results of this study confirm the results of previous reports indicating that the probability 
of developing PMWS increases in animals infected with PCV2 and other agents such as 
PRRSV or PPV.  
 Results of all these studies revealed that the presence of PCV2 is essential, but 
several other pathogens also play a role in PCVAD development and progression 
 
Transmission 
 Transmission of PCV2 can occur through several routes of exposure, including 
oro-nasal, intranasal, and subcutaneous (Allan et al., 1999; Pogranichniy et al., 2000; 
Bolin et al., 2001). The high prevalence of PCV2 in swine herds worldwide indicates that 
PCV2 transmission is effective (Kristensen et al., 2009) and is most likely transmitted 
horizontally between pigs via oro-fecal and respiratory routes (Caorioloui et al., 2006) 
but can also be transmitted vertically (West et al., 1999; Ladekjær-Mikkelsen et al., 
2001).  Vertical transmission occurs directly from mother to embryo, while horizontally 
transmission occurs through contact with members of the same species, excluding parent 
and offspring relations. For example, horizontal transmission occurs when non-infected 
pigs are exposed to infected pigs (Grau-Roma et al., 2011).  
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 Horizontal Transmission: Several studies have demonstrated that PCV2 DNA 
can be detected in nasal, tonsillar, fecal swabs (Bolin et al., 2001; Harms et al., 2001; 
Shibata et al., 2003; Caprioloi et al., 2006 and Patterson et al., 2010) as well as 
tracheobronchial and urinary swabs (Segalés et al., 2005). Since PCV2 is shed through 
multiple routes, horizontal transmission is the most efficient method of viral proliferation 
within a population. It has been demonstrated that PCV2 targets the lymphoid tissues 
(Opriessnig et al., 2007) and is shed between infectious and susceptible pigs through 
feces, urine, respiratory, nasal, and oral secretions (Segalés et al., 2005) and residues for 
prolonged periods of time (Bolin et al., 2001). PCV2 DNA has also been detected in milk 
and semen, which suggest additional potential routes of transmission (Krakowka et al., 
2000). Intranasal exposure is the most common route of natural PCV2 transmission; 
however, pigs can be experimentally infected by intramuscular, intrauterine, oral, and 
intranasal methods of inoculation (Madson et al., 2011; Segalés et al., 2012 and Rose et 
al., 2012).  
 In order to understand the shedding mechanism and infection dynamics of PCV2, 
Patterson and others (2010) conducted a study using 26 experimental pigs for inoculation. 
Methods of inoculation included: pooled oral samples given intraperitoneal (IP), pooled 
fecal samples given IP, pooled nasal samples given IP, pooled oral samples given orally, 
pooled fecal samples given orally, and pooled nasal samples given intranasally (IN) and 
intramuscular (IM) injections. The pigs given the three different IP inoculations 
demonstrated seroconversion of anti-PCV2 antibodies and developed PCV2 viremic 
conditions.  Pigs given intranasal inoculations also developed PCV2 viremic conditions.  
Of the four pigs given fecal samples orally, two displayed signs of infection. Of the three 
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pigs given IM injections, one became viremic. Pigs given oral samples orally did not 
develop PCV2 viremia.  The results of this study indicate that under experimental 
conditions, PCV2 is predominately shed through nasal, oral and fecal secretions. 
 Another study conducted by Yang and others (2003) demonstrated that PCV2 
could be transmitted through feces. In this study, 97 pigs were used to extract fecal and 
intestinal samples. Of the 97 pigs, 63 pigs demonstrated symptoms of enteric disease, and 
the other 34 pigs showed no signs of gastrointestinal complications. Polymerase chain 
reaction (PCR) was used to detect the presence of PCV2 DNA in the intestinal and fecal 
samples. Of the 63 enteric diseased pigs, 18 tested positive for PCV2, where PCV2 DNA 
was detected in 14 intestinal samples, and in 4 fecal samples. The results of this study 
indicate that PCV2 can be successfully shed and transmitted through fecal matter.  
 A study performed by Andraud and others (2008) demonstrated that transmission 
was more efficient when non-infected pigs were housed in the same pens as infected pigs 
compared to non-infected pigs housed in separate pens. Although this study demonstrated 
that PCV2 transmission occurred more frequently when non-infected pigs were housed in 
the same pens as infected pigs, indirect infections can also occur even when infected and 
non-infected pigs were housed in separate pens. 
 In a study performed by Kristensen and others (2009), 12 swine herds were used 
to verify if pigs taken from PMWS-unaffected herds could develop PMWS after being 
exposed to pigs from PMWS-affected herds. All of the herds tested positive for PCV2 
and eight of the herds were PMWS-affected, while the other four were PMWS-
unaffected. Some PMWS healthy pigs shared pens with PMWS-affected pigs, while other 
PMWS healthy pigs where placed in pens next to PMWS-affected pigs. Furthermore, 
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some PMWS healthy pigs where also placed in pens across the aisle from PMWS-
affected pigs. Of the PMWS healthy pigs, ten housed with PMWS-affected pigs, three 
housed in pens neighboring PMWS-affected pigs and one housed across the aisle form 
PMWS-affected pigs demonstrated clinical symptoms of PMWS. The results of this study 
verified the assumption that direct and indirect exposure can induce PMWS. 
 Although little research has been done on PCV2 transmission from infected pork 
products, some researchers have suggested the possibility of transmission through meat in 
slaughter houses and packing plants. Allan and others (1994) determined that PCV2 is 
stable at a pH of 3, which led to a study conducted Opreissnig and others (2009b) 
demonstrating that it is likely that meat from a PCV2-postive animal could be capable of 
transmission because slaughter houses and packing plants rarely reach a pH that lower 
than 6.2. The United States swine industry increased the exportation rate of pork products 
from 422,373 metric tons in 1996 to 1,262,499 metric tons in 2006 (Opriessnig et al., 
2009b). Pork products are exported from the United States to several countries including 
Japan, South Korea, Mexico, Canada, China, and Taiwan as well as numerous other 
countries. Although it is beneficial for the United States swine industry to increase the 
exportation rate of pork products, it also increases the risk of transmitting diseases 
between countries. Opriessnig and others conducted a study to determine if PCV2 was 
transmissible through consumption of meat and bone meal. Since PCV2 has been 
detected in lymphoid tissue, bone marrow (Bolin et al., 2001) and heart tissue (Kennedy 
et al., 2000) understanding the relationship between oral consumption and PCV2 
infection is an important piece of the transmission mechanism. The objectives of this 
study were to determine if PCV2 infected pork products contained PCV2 DNA or antigen 
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and if PCV2 infected pork products were capable of infection. Tissue samples derived 
from three 7-week old pigs inoculated intramuscularly and intranasally with PCV2. The 
three pigs were euthanized at 14dpi and tissue samples were collected including skeletal 
muscle, spleen, tonsil, lymph nodes, and bone marrow from three previously infected 
pigs. Then fifteen 2-week old colostrum-deprived crossbred pigs were randomly assigned 
to five treatment groups each in a different room. The treatment groups were as follows: 
group 1- controls (n=3), group 2- skeletal muscle given orally (n=3), group 3 bone 
marrow given orally (n=3), group 4lymphiod tissue given orally (n=3), group 5 PCV2 
inoculum via stomach tube (n=3). Pigs given skeletal muscle, bone marrow, or lymphoid 
tissue developed viremic conditions after 7dpi. In addition, all of the pigs in the study 
became PCV2 positive and microscopic lesions from lymphocytic depletion were 
developed in nine of the fifteen experimental pigs. The results of this study indicate that 
PCV2 infection can be transmitted through uncooked skeletal muscle, bone marrow, and 
lymphoid tissue via oral consumption. 
 The results from all of these studies demonstrate that PCV2 horizontal 
transmission can occur through a wide range of secretions and excretions as well as 
consumption and can be detected in numerous regions of the body. 
 Vertical Transmission From Infected Sows: Although breeding females under 
field conditions can be infected with PCV2, sows typically demonstrate subclinical 
infections and do not display clinical symptoms (Madson et al., 2011). However, if sows 
become viremic during pregnancy, PCV2 can spread across the placenta and infect 
fetuses. Vertical transmission, which occurs directly from dam or sire to embryo has been 
supported by numerous studies. Natural PCV2 infection in pregnant sows can result in 
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late term abortions as well as increases the mortality in live-born piglets (Calsamiglia et 
al., 2007). Sows that have been given PCV2 vaccinations can protect their offspring 
through passive immunity.  In a study performed by Tomás and others (2008) involving a 
PCV2 experimental infection observed that piglets that did not receive colostrum had a 
higher incidence of PMWS.  In addition, Calsamiglia and others (2007) demonstrated that 
piglets produced from sows with low maternal antibody titres had higher rates of 
mortality compared to piglets produced from sows with higher levels of maternal 
antibodies. In a review paper written by Grau-Roma and others in 2011, demonstrated 
that sows with higher PCV2 viremia had increased piglet mortality rates. 
 Preceding studies have described an occurrence known as the “litter effect” which 
involves high mortality in post-weaning multisystemic wasting syndrome (PMWS) 
affected farms. In order to examine the litter effect, Calsamiglia and others (2007) 
conducted a study to evaluate litter mortality in different PMWS affected farms and to 
further characterize its relation to sow parity, PCV2 infectious state and PCV2 antibody 
titres. The present study was performed in seven farms that demonstrated PMWS in 
nurseries and/or fattening areas. From each farm 15 sows were randomly selected for the 
experiment (105 sows). Once the sows had farrowed, four piglets were randomly selected 
from each sow (60 piglets per farm; 420 piglets total). The 420 selected pigs were 
observed for a seven-month period where pathological exams were routinely performed 
to evaluate the development of PMWS. Of the total number of piglets used in the 
experiment 104 piglets died (24.8%) and 40 (38.5%) were diagnosed with PMWS. 
Because mortality due to PMWS infection is associated with sow PCV2 viremia, the 
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results of this study suggest that sow infection status around farrowing, plays a significant 
role in the pathogenesis of the disease progression on a litter. 
 It has recently been demonstrated that transplacental transmission of PCV2 can 
occur from infected pregnant sows (Park et al., 2005).  In a study performed eight 
pregnant sows, serologically negative for PCV2, PPV, and PPRSV were used for 
experimental infection.  Each sow was randomly assigned to either a PCV2 infected 
(n=6) or control (n=2) group.  The sows assigned to the PCV2 infection group were 
infected three weeks prior to the expected farrowing date via intranasal inoculations 
containing 6 ml of tissue culture fluid (1.2 x 10
5
 TCID50/ml) of an isolated PCV2 strain 
(SNUVR000473). Of the experimental sows used in this study, all six aborted before 21 
dpi, producing 65 stillborn and 10 liveborn piglets. In contrast, both PCV2-negative 
control sows remained clinically healthy and demonstrated normal gestations delivering 
17 liveborn piglets at 114 days of gestation. In addition, the piglets delivered from control 
sows did not express presence of PCV2. Of the tissue samples tested, the results suggest 
that PCV2 travels to lymphoid tissues from the placenta via the bloodstream and 
predominantly replicates in these tissues in prenatal fetuses. 
 The results from this study indicate that PCV2 is capable of inducing reproductive 
failure in pregnant sows. Previous studies have demonstrated that PCV2 is detectable in 
aborted fetuses at all stages of gestation (Kim et al 2004b) and is able to replicate in 
fetuses after intra-fetal inoculation at any stage of gestation (Sanchez et al., 2001). The 
combination of results from preceding experiments, as well as the present study strongly 
denotes that PCV2 is capable of crossing the placenta at any stage of gestation. 
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 The results from these previous studies suggest that sows challenged with PCV2 
under experimental conditions as well as sows experiencing natural PCV2 infection have 
an increase in the number of stillborn and mummified fetuses (Park et al., 2005) and that 
aborted fetuses from pregnant sows can express PCV2 antigen in the myocardium (West 
et al., 1999). 
 Once PCV2 infection occurs, shedding of the virus can occur via bodily fluids 
(Ha et al., 2009). In a study performed by Ha and others, colostrum and milk from PCV2 
infected sows were evaluated for the presence of PCV2. Pregnant sows were randomly 
selected and assigned to a PCV2 infected (n=6) or a control (n=2) group. Sows from the 
infected group were inoculated intranasally at 93 days of gestation, with an isolated 
PCV2 strain (SNUVR000470). In addition all of the sows from both groups remained 
clinically normal, without farrowing prematurely and delivered liveborn pigs between 
114 and 115 days of gestation. Colostrum samples were collected from all eight sows 
immediately after farrowing. Milk samples were also collected at 1, 3, 6, 9, 12, 15, 18, 
21, 24, and 27 days of lactation from all eight sows.  
 Of the colostrum samples taken from each infected sow, all six milk whey and 
pellet samples were positive for PCV2 via PCR. In addition, both of the colostrum 
samples taken from control pigs were negative for PCV2 via PCR. Of the milk samples 
taken from each infected sow, all six milk whey samples were positive for PCV2 via PCR 
from day 3 lactation until day 27; however only three of the pellet samples were positive 
for PCV2 via PCR at 3 days lactation. From the control sows, all milk whey and pellet 
samples for both colostrum and milk were negative for PCV2 for all time periods of 
lactation. Previous studies have reported that PCV2 viremic sows and low PCV2 
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antibody titres in infected sows are associated with piglet mortality (Calsamiglia et al., 
2007). The results of the present study support these preceding studies and indicate that 
PCV2 DNA is shed in both colostrum and milk from experimentally infected pregnant 
sows causing an increase in piglet mortality. 
 Vertical Transmission From Infected Fetuses: Fetuses derived from sows 
infected intranasally with PCV2, have detectable amounts of PCV2 DNA and antigen 
present in lymphoid tissues, myocardial tissues, and other organs, which indicate PCV2 
replication (Park et al., 2005). In stillborn and mummified fetuses, PCV2 antigen has also 
been detected in myocardial tissues and tonsils (Madson et al., 2009). It appears that 
PCV2 predominately targets myocardial tissues for replication in stillborn and 
mummified fetuses, which can cause vasculitis and cardiac failure. 
 Vertical Transmission From Infected Boars: Numerous reports have detected 
PCV2 DNA in semen from infected boars (Larochelle et al., 2000; Kim et al., 2003a; 
McIntosh et al., 2006 and Madson et al., 2008); therefore, several experiments have been 
conducted to determine if PCV2 infected semen can be infectious to piglets.  
 A study led by Larochelle and others, determined that PCV2 can be shed in semen 
from infected boars. In this study, 4 boars were house in isolated pens, and infected 
intranasally with PCV2 isolate LHVA-V53.  Semen and serum samples were routinely 
collected to evaluate the presence of PCV2. The results of this experiment demonstrated 
that all 4 boars shed PCV2 DNA in their semen. Although it was not determined if the 
PCV2 was infectious, the authors indicated the need for follow up studies to conclude the 
infectious state of PCV2 DNA shed through semen (Larochelle et al., 2000). 
 PCV2 DNA has been found in testes and accessory glands of infected boars 
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(Opriessnig et al, 2006). The shedding period for PCV2 in semen from experimentally or 
naturally infected boars can occur from 6 days (Madson et al., 2008) to 27 weeks 
(McIntosh et al., 2006). Reproductive failure can be experimentally induced by 
artificially inseminating naïve sows with PCV2 infected semen (Madson et al., 2009). 
 In another study conducted by Madson and others (2009), PCV2-free sows were 
artificially inseminated with PCV2-spiked semen to try to induce infection. Nine specific-
pathogen-free (SPF) sows were broken into three groups. Group 1 sows were negative 
controls and were artificially inseminated with PCV2-negative semen, group 2 sows were 
artificially inseminated with semen containing PCV2a, and group 3 sows were artificially 
inseminated with semen containing PCV2b. The three sows given PCV2a semen failed to 
maintain pregnancy, therefore no pigs were born live, stillborn, or mummified. The three 
sows artificially inseminated with semen containing PCV2b produced 35 piglets. Of these 
piglets, only 8 were born alive, 2 were stillborn, and 25 were mummified. The stillborn 
piglets developed lesions due to myocardial dysfunction and cardiac dilation. In addition, 
all live-born, stillborn and mummified fetuses demonstrated detectable PCV2 antigen in 
myocardial tissue indicating that myocardial tissue is the preferred target for PCV2 
replication in fetuses. The results of this study suggest that PCV2-spiked semen can 
induce viremic conditions in the sow and stimulate intrauterine infections causing 
viremia in fetuses and should therefore be considered for PCV2 transmission (Madson et 
al., 2009). 
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Porcine Circovirus Associated Diseases 
 PCV2 infection may result in the progression of several distinct syndromes and 
disease including post-weaning multisystemic wasting syndrome (PMWS), porcine 
dermatitis and nephropathy syndrome (PDNS), porcine reproductive failure, porcine 
respiratory complex, and PCV2-associated enteritis. The wide spectrum of clinical 
manifestations is problematic for developing strategies for PCV2 diagnosis and 
prevention, and presents a difficult challenge for researchers such as veterinarians, 
pathologists, virologists, and epidemiologists (Chae, 2005). 
 Post-weaning Multisystemic Wasting Syndrome: Post-weaning multisystemic 
wasting syndrome (PMWS) was first discovered in Canada in 1991(Gagnon et al., 2007); 
however, occurrences have also been detected worldwide (Chae, 2005). Although Canada 
first recognized PMWS as a newly emerging disease in 1996 causing wasting in post-
weaned pigs, it is currently recognized as a disease worldwide (Chae, 2005). PCV2 has 
been identified as the etiologic agent responsible for causing PMWS (Allan et al., 1998a; 
Ellis et al., 1998; Hamel et al., 1998).  Numerous PMWS outbreaks have been reported 
from swine herds from major pig producing areas in the world such as North and South 
America, Europe, and Asia (Chae, 2004), which has caused major economic concern. In 
addition, PMWS occurs in both endemic and epidemic forms in Asia and Europe.  
 PMWS is typically observed in pigs that are between 25 and 120 days of age, with 
the highest number of cases occurring between 60 and 80 days of age (Chae, 2004). 
Characteristic symptoms of the syndrome include weight loss, dyspnea, jaundice, 
enlarged lymph nodes, hepatocyte necrosis, multifocal lymphohistiocytic pneumonia, 
lymphocyte depletion, and multinucleated giant cell formation (Harding, 1997 and 
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Gagnon et al., 2008). PMWS-affected pigs will also experience a reduction in circulating 
lymphocytes causing a decline in immunological function (Takahagi et al., 2009), though 
only 10-30% of naturally PCV2 infections progress into PMWS (Darwich et al., 2004).  
 In addition, lesions consisting of clusters of globular intracytoplasmic inclusion 
bodies are characteristic of PMWS (Sorden 2000). Other lymphoid lesions can be 
identified in numerous tissues in affected animals such as tonsils, Peyer’s patch, spleen, 
thymus, and lymph nodes (Darwich et al., 2004).  Although these lesions are indicative of 
PMWS, not all affected animals will demonstrate theses lesions; therefore there are other 
methods that can determine if a PCV2 infection will progress into PMWS. For example, 
during necropsy PMWS-affected pigs can exhibit lungs that are tan in color, kidneys may 
have white stripes or spots, and enlargement of lymph nodes (Gillespie et al., 2009). 
 PMWS can also alter the cytokine balance and expression in affected pigs. 
PMWS stimulates and upregulation of several cytokines including interleukin 10 (IL-10) 
and interferons such (interferon-gamma) INF-γ. The over-production of IL-10 in the 
thymus, can lead to atrophy of the thymus, and thymic depletion. In addition, PMWS can 
elicit the over-production of INF-γ in the tonsils  (Darwich et al, 2003). 
 In a study performed by Darwich and others in 2003, to analyze the cytokine 
expression patterns in different lymphoid tissues lymphoid tissues in naturally PCV2-
infected, PMWS-affected pigs. During the study, 10 eight-week old PCV2 positive pigs 
showing characteristic signs of PMWS and 5 healthy control pigs were used for the data 
collection. Blood samples and lymphoid samples were taken from each animal to 
correlate the cytokine expression pattern with haematological and histopathological 
results. Of the ten PCV2 positive PWMS-affected pigs, 3 had severe thymic depletion 
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and atrophy. The other 7 PCV2 positive PWMS-affected pigs demonstrated enlarged 
lymph nodes, interstitial pneumonia and lymphoplasmacytic hepatitis. The histological 
lesions observed in the 10 PCV2 positive PWMS-affected pigs displayed mild to severe 
lymphocyte depletion.  
 PWMS-affected pigs demonstrated a cytokine mRNA expression alteration of 
several important cytokines involved in driving a specific immune response in different 
organs being examined (Darwich et al. 2003). These cytokines include IL-12, IL-10, IL-
2, IL-4 and INF-γ. From the cytokine imbalance, IL-10 was notably over expressed in the 
thymus as well as a decrease in expression of IL-2 and IL-12 in the spleen.  IL-10 plays a 
role in anti-inflammatory effects and regulates natural killer and B-cell growth. The over 
expression of IL-10 in the thymus could be responsible for the origin of T-cell depletion, 
which could have significant effects on T-cell function. IL-10 upregulation also suggests 
the presence of an active immune stressor. IL-2 and IL-12 are known as T-cell-
stimulating factors. IL-2 is involved in the growth and proliferation of T cells and IL-12 
plays a role in the differentiation of naïve T-cells into Th1 cells. The results from this 
study indicate that the increased levels of IL-10 mRNA as well as the overall cytokine 
imbalance could be involved with T-cell immunosuppression.  
 PMWS is known as a multifactorial syndrome. PCV2 infection is necessary for 
the development of PMWS, though singular PCV2 infection is not sufficient enough to 
elicit PMWS progression (Calsamiglia et al., 2007). Development of PMWS is dependent 
upon several factors such as sow immune status, herd management, co-infections, and 
virulence of the infecting strain.  
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 In order to diagnosis PWMS, three criteria must be met: (i) clinical signs must be 
expressed, such as weight loss, dyspnea, jaundice, and wasting (ii) PCV2-characteristic 
microscopic lesions must be present, including lymphoid depletion or histiocytic 
replacement of follicles in lymphoid tissues and (iii) PCV2 antigen or nucleic acid must 
be present within lesions (Chae, 2004 and Sorden 2000). All three criteria must be met in 
order to establish PMWS diagnosis; therefore, detection of PCV2 alone does not suggest 
PMWS, instead just a PCV2 infection. To determine diagnosis, immunohistochemistry 
and in situ hybridization techniques are used to link virus and tissue lesions (Chae, 2004). 
 To establish an accurate diagnosis of PMWS, lymphoid tissues such as spleen, 
tonsil and thymus as well as pancreas, liver, lung and kidney tissues should be collected 
for testing. In a study led by Opriessnig and others in 2004, a specific scoring system was 
developed to evaluate the extent of PCV2 infection in seven types of lymphoid tissues. 
Each lymphoid tissue was given a score ranging from 0 to 9, where the scoring system 
evaluated each tissue based on three categories including lymphoid depletion (0 to 3), 
granulomatous inflammation (0 to 3), and PCV2-immunohistocehimstry (0 to 3). 
Although they scoring system was subjective, it enabled a consistent evaluation of each 
tissue affected from infection. 
 Cases of PMWS have been reported in all types of swine operations including 
farrow-to-feeder, farrow-to-finish, off-site nursery, and grower pig farms. Small 
operations with as little as 50 sows as well as larger operations with up to 1200 sows 
have reported PMWS signs (Harding and Clark 1997). Therefore, it appears that every 
herd can potential experience PMWS. Since most PCV2 infections involve co-infections, 
it has been suggested that various pathogens could potentially utilize the same 
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mechanisms as PCV2 to evade the immune system. In addition, simultaneous infections 
of PCV2 with other viruses such as porcine reproductive and respiratory syndrome virus 
(PRRSV), porcine papovirus (PPV) can exacerbate the condition of the infected animal 
(Krakowka et al., 2000). Therefore it has also been proposed that PCV2 infections may 
potential play a role in increasing host susceptibility to other pathogens. 
 PCV2-associated Enteritis: Although incidences of PCV2-associated enteritis 
occur less frequently compared to other PCV2-associated syndromes and diseases, it can 
have detrimental effects on many systems of the body. Affected pigs become heavily 
diarrheic and experience inflammation of the large intestine as well as decreased weight 
gains (Kim et al., 2004a). Younger pigs are more vulnerable and are typically affected 
between 40 and 70 days of age (Chae, 2005).  
 Diagnosis of PCV2-associated enteritis is based on three criteria: (i) presence of 
diarrhea, (ii) presence of characteristic microscopic lesions in the Peyer’s patches but not 
in the lymph node, and (iii) presence of PCV2 within these lesions (Kim et al., 2004a; 
Chae, 2005). Because PCV2-associated enteritis symptoms are clinically and 
histologically similar to PMWS, accurate diagnosis is difficult. Therefore, lesions present 
in the Peyer’s patches but absent in lymph nodes is indicative of PCV2-associated 
enteritis, while lesions present in the lymph nodes suggest PMWS (Kim et al., 2004a). 
 Porcine Respiratory Disease Complex: Another PCV2 associated disease, which 
causes severe health issues in growing and finishing pigs is porcine respiratory disease 
complex (PRDC). Pigs who are clinically affected are typically between 16 to 22 weeks 
of age, and show signs of slow growth, low feed efficiency, anorexia, fever, cough, and 
dyspnea (Halbur, 1998b; Thacker, 2001). Pneumonia can also be seen in pigs affected 
45 
 
with PRDC, which is caused from a combination of both viral and bacterial agents (Kim 
et al. 2003b). The co-infecting viral agents include PCV2, PPV, PRRSV and SIV and co-
infecting bacterial agents include Mycoplasma hyopneumoniae, Actinobacillus 
pleuropneumoniae and Pasteurella multicida (Halbur, 1998b; Thacker, 2001).  
 Symptoms seen in PRDC-affected pigs are similar to those observed in PMWS-
affected pigs; however, PRDC affects older pigs typically between 16 and 22 weeks of 
age, where PMWS affects younger pigs at about 8 to 16 weeks of age. Pigs affected with 
PRDC due to PCV2 infections usually express widespread granulomatous inflammation, 
and intracytoplasmic basophilic viral inclusion bodies (Kim et al., 2003b). In addition, 
PCV2 also causes lesions associated with bronchointerstitial pneumonia (Chae, 2005). 
Accurate diagnosis of PRDC is based on four criteria: (i) the presence of respiratory 
signs, (ii) the presence of characteristic pulmonary microscopic lesions, (iii) the presence 
of PCV2 within these lesions, and (iv) the absence of the characteristic lesions associated 
with PMWS in the lymphoid tissues (Chae, 2005). 
 Porcine-associated Reproductive Failure: PCV2 has the potential to infect 
pregnant sows, which can induce abortion and cause fetal deaths (Park et al., 2005). 
Porcine-associated reproductive failure was first reported in Canada in 1999 (West et al., 
1999). Gilts in start up operations are typically affected with porcine-associated 
reproductive failure and show clinical signs of increased abortion, still births, delivery of 
fetal mummies, and increased mortality in pre-weaning piglets (West et al., 1999; 
Ladekjaer-Mikkelsen et al., 2001; O’Connor et al., 2001; Kim et al., 2004b; Gillespie et 
al., 2009). In a review paper conducted by Chae in 2005, several previous studies are 
discussed indicate that sows infected with PCV2 had higher incidences of stillborn and 
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premature piglets. PCV2-associated reproduction failure can occur through all stages of 
gestation, which can be problematic for swine producers (Sanchez et al., 2001).  
 In addition, PCV2 DNA has been detected in the testes as well as accessory 
glands of infected boars (Opriessnig et al, 2006), which indicates the potential to induce 
reproductive failure can be induced by artificially inseminating naïve sows with infected 
boars (Madson et al., 2009). A study led by Kim and others in 2004, tested 350 
aborted/stillborn fetuses for presence of PCV2, PPV, and PRRSV (Kim et al., 2004b). 
The aborted/stillborn fetuses were collected from 321 Korean farms. Of 350 fetuses, 43% 
tested positive for one of the three viruses. In addition, 10% of the fetuses tested positive 
for a singular infection of PCV2.  The results of this study suggest that PCV2 could 
potentially induce reproductive failure (Kim et al., 2004b). 
 Another study performed by O’Connor and others in 2001 described an acute 
reproductive failure outbreak at a farm consisting of 3,000 sows. During an 8-week 
period, the number of mummified fetuses increased to 15%, as well as the number of 
stillborns, which increased to 8% and the rate of pre-weaning mortality rose to 11% 
(O’Connor et al., 2001). Tissue samples were taken from two stillborn fetuses and two 
piglets, which died shortly after birth, were evaluated for the presence of PCV2. Of the 
four samples, PCV2 was detected in the heart of two of the piglets, as well as in the lung 
and spleen tissues in the other two piglets. The results from this study reveal that PCV2 
can be transmitted vertically, inducing PCV2 infection in piglets in utero. 
 Porcine Dermatitis and Nephropathy Syndrome: The first incidence of porcine 
dermatitis and nephropathy syndrome (PDNS) was identified in the United Kingdom in 
1993 (Smith et al., 1993; White and Higgins, 1993; Gillespie et al., 2009). Since the 
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original discovery, PDNS has also been recognized in numerous swine producing 
countries (Drolet et al., 1999). Although the disease typically affects nursery and grower 
pigs and is often fatal (Opriessnig et al., 2007), PDNS has also been seen in finishing pigs 
and replacement gilts (Chae et al., 2005). The most predominate indication of PDNS; 
particularly in the acute phase of the disease is the development of red and purple skin 
lesions located on limbs and abdomen and hindquarters (Drolet et al., 1999; Harding, 
2004; Gillespie et al., 2009). Other characteristic signs seen in PDNS-affected pigs 
include fever, weight loss, lethargy, as well as loss of appetite. PDNS-affected pigs can 
also experience edema including enlarged, pale kidneys, enlarged lymph nodes, and 
gastric ulcerations (Droplet et al, 1999). Pigs experiencing severe cases of PDNS can also 
exhibit stiff gait or reluctance to move, rapid, dyspnea or tachypnea (Drolet et al., 1999). 
Farms that observe severe anorexia, weight loss, and skin lesions typically experience 
higher mortality rates. A review conduced by Drolet and others in 1999 suggest that 
PDNS is a vascular disease that emulates other immune-mediated disorders to induce 
acute inflammation. Although PCV2 was first reported in association with PDNS in 2000 
(Rosell et al., 2000), previous research from 1990 indicates that swine herds from 
Northern Ireland experiencing cases of PDNS exhibited granulomatous lymphadenitis 
associated with PCV2 antigen in affected pigs (Allan et al., 2000c). 
 Wellenberg and others led a case-control study in the Netherlands to investigate 
the role of PCV2 in the development of PDNS. In this study, 3 PDNS-affected pigs were 
selected from 10 different Dutch swine herds (n=30).  The selected pigs displayed 
symptoms including lethargy, fever, as well as red and purple skin lesions located on the 
abdomen and limbs. Several pigs demonstrated enlarged grey-brown kidneys with white 
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spots on the renal cortex in addition to hemorrhagic lymph nodes during necropsy 
examinations. The authors of this study were not able to identify PCV2 via 
immunohistochemistry (IHC); however, using PCR amplification, all of pigs tested 
positive for the presence of PCV2, 33% pigs tested positive for the presence of PPV, and 
83% tested positive for the presence of PRRSV. In addition, PDNS-affected and non-
affected pigs were evaluated for the presence of anti-PCV2 antibodies. The results of this 
study indicated that there is a significant association between the level of anti-PCV2 
antibody titres and the development of PDNS (Wellenberg et al., 2004).  
 In another study, Sipos and others (2005) evaluated the systemic cytokine patterns 
in 5 PDNS-affected pigs, 5 PMWS-affected pigs, and 5 control pigs to increase the 
understanding of PDNS pathogenesis. PDNS-affected pigs demonstrated an upregulation 
in the expression of interleukin 1α (IL-1α), interleukin 6 (IL-6), interleukin 10(IL-10), 
and interferon gamma (INF-γ) compared to control pigs. In addition, PDNS-affected pigs 
experienced a downregulation in interleukin 2 (IL-2), interleukin 4 (IL-4) compared to 
control pigs.  Although the results of this study are indicative of proinflammatory 
conditions, more research is necessary to gain a more complete understanding of PDNS 
pathogenesis (Sipos et al., 2005). 
 
PCV2 Diagnosis 
 Clinical symptoms of an acute PCV2 infection occur in a variety of forms. 
Several symptoms such as weight loss, paleness of skin, respiratory difficulty, and 
diarrhea are characteristic indicators of PCV2 infections, but require further investigation 
for a precise diagnosis. Other indications can be observed upon necropsy such as 
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lymphocyte depletion, inflammation of lymphoid tissues, granulomatous, and detectable 
levels of PCV2 in damaged tissues. Currently the most accurate method diagnosing an 
acute PCV2 infection is to evaluate the severity of clinical symptoms.  
 Although characteristic manifestations of porcine circoviruses associated diseases 
(PCVAD) such as PMWS, PDNS, and PRDC, are usually obvious and can easily be 
identified, laboratory procedures produce the most definite diagnosis.  
  Laboratory techniques such as immunohistochemistry (IHC) and in situ 
hybridization (ISH) are used to detect PCV2 in selected tissue samples. IHC is used to 
detect specific antigens in cells of selected tissue by combining immunological, 
histological, and biochemical techniques using a specific antigen/antibody reaction 
tagged with a visible label. IHC uses polyclonal and monoclonal antibodies to identify 
the presence of PCV2 antigen. ISH is a type of hybridization procedure used to identify 
the location of DNA or RNA sequences in selected tissue  
 Serological tests are typically used for large-scale PCV2 diagnosis. Because 
certain pigs can be seropositive, but do not demonstrate clinical symptoms of PCVAD, 
gaining an accurate diagnosis can be problematic. For accurate diagnosis serological tests 
should be performed at the herd level and not on individual pigs. Therefore number of 
pigs being evaluated should be considered when conducting serological tests (Gillespie et 
al., 2009).  Quantitative real-time PCR (qPCR) is another method used for detecting 
PCV2. This procedure is based off of traditional PCR and is used to amplify a targeted 
DNA; however qPCR also quantifies the level of targeted DNA present in the sample. 
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 Diagnostic accuracy is the essential component for treating viral infections 
appropriately. In addition, early diagnosis of PCV2 infections is crucial in preventing 
clinical outbreaks and maintaining a healthy swine herd.   
 
PCV2 prevention and Control 
 Mortality due to PCVAD significantly impacts the global swine industry. PCV2 is 
an economically important pathogen because of its infectious capability, which has the 
potential to infect herd populations. In addition, the wide variety and severity of PCV2 
symptoms also complicates treatment options. Currently there is no specific treatment 
available for PCV2 infections as well as any of the PCV2-associated diseases.  
 Factors such as PCV2 isolates, co-infections, immune stimulation, as well as host 
susceptibility play a crucial role in disease progression; consequently accurate prognosis 
is dependent upon these influential factors. For instance, a large number of PCV2 
infections involve co-infections; therefore prognosis is also dependent upon accurate 
identification of other pathogenic agents infecting the animal.  
 Prevention can be challenging since disease outbreaks have been reported in 
farms with strict management practices. Vaccinating for co-infecting agents can help 
reduce the spread of PCV2; however, many co-infecting agents exist further complicating 
this prevention method. Good herd management techniques are essential for disease 
prevention. These management techniques can include reducing stress, minimizing the 
mixing/sorting of pigs, cleaning and disinfecting barns, keeping buildings at the optimal 
temperature for size and age of pig, decreasing humidity in barns, maintaining optimal air 
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quality via proper ventilation, reducing overstocking of pens, as well as supporting proper 
animal hygiene (Harding et al, 2004; Gillespie et al., 2009).  
 In a review conducted in 2007, Opriessnig and others discussed several methods 
such as disinfection to reducing viral replication and PCV2 outbreaks. Chemicals such as 
sodium hydroxide, Virkon S (Antec International, UK), Roccal D Plus (Parmacia and 
Upjohn, US), Clorox Bleach (Clorox Company, US), and Tex-Trol (Bio-Tek Industries 
Inc, US) have demonstrated a reduction in the spread of PCV2 in laboratory settings; 
though, these chemical disinfectants have not yet been tested in commercial settings.  
 In addition, Madec and others developed a 20-point plan to reduce the impact of 
PCV2. The most effective preventative measure is assuring good management techniques 
that minimize stress, eliminate co-infections that trigger PCV2 infection to progress to 
PCV2-associated disease. In order to maintain a healthy herd, at least the first 16 points 
should be adopted into typical swine management techniques to ensure the most effective 
viral prevention (Madec et al., 1999). 
 
PCV2 Vaccinations 
 It is imperative to note that PCV2 is the primary causative agent responsible for 
stimulating the development of PCVAD; however, several studies have demonstrated that 
the use of vaccines has a significant impact in growing pigs (Horlen et al., 2008; 
Fachinger et al., 2008; Kixmoller et al., 2008; Opriessnig et al., 2009; Neumann et al., 
2009). A study conducted by Jacela and others (2011) demonstrated a significant increase 
(P< 0.001) in growth performance in vaccinated pigs compared to control individuals. 
The results of this study, provides significant evidence that the use of PCV2 vaccines has 
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a significant impact on growth rates in feeder pigs, and is useful in controlling the 
development of PCVAD. 
 Current PCV2 vaccines include Ingelvac® CircoFLEX™, Porcilis® PCV, 
Suvaxyn PCV2® One Dose, Circumvent PCV ™, and Circovac®. The outer capsid 
proteins of PCV2, which are encoded in open-reading frame 2 (ORF2) appear to be 
highly immunogenic and are therefore the most antigenically significant component of 
the vaccine (Burch, 2008). Both Ingelvac® CircoFLEX™ (Boehringer Ingelheim), and 
Porcilis® PCV (Schering-Plough/ Intervet) are capsid based vaccines. Ingelvac® 
CircoFLEX™ is a PCV2 subunit vaccine that uses capsid proteins as antigens and killed 
baculovirus vectors to prevent PCV2 viremia and shedding (Boehringer Ingelheim). In 
order to produce the antigen for the vaccine, the ORF2 gene encoding the PCV2 capsid 
protein is placed into the baculovirus vector, which is injected into the host. Using this 
vaccine can be very beneficial to swine producers because it is a single-dose vaccine 
requiring 1 ml injected intramuscularly, which reduces the stress on the pig as well as 
decreases the labor/production costs. In addition, this vaccine can be administered in 
healthy pigs as early as 3 weeks of age providing early and sustained immunity 
(Boehringer Ingelheim).  
 Porcilis® PCV is another subunit vaccine, which uses PCV2 capsid proteins to 
stimulate the immune system and diluvac tocopherol as an adjuvant (Burch, 2008). This 
vaccine can be given to pigs as early as 3 weeks of age; however, it requires 2 doses, 
which increases stress on the animal as well as potentially increase production costs. 
 Circumvent G2® is similar to Ingelvac® CircoFLEX™, and uses an inactivated 
baculovirus vector to prevent against PCV2 viremia and shedding. There are many 
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advantages to using this vaccine because it offers a wide range of dosing options. 
Currently Circumvent G2® is the only PCV2 vaccine approved to use in pigs as early as 
3 days of age. In addition, this vaccine can be administered in one or two dose methods, 
which allows the producer to choose which dosing program would best fit their operation. 
The one dose method requires a 2 ml intramuscular injection, which is recommended for 
pigs that are exposed to PCV2 after 7 weeks of age, and if the co-infection disease 
pressure is low (Intervet). This is beneficial to the producer because labor is a limiting 
factor, and this reduces stress to the animal. The two-dose method requires an initial 1 ml 
intramuscular injection as early as 3 days of age, and a second 1 ml dose 3 weeks later. 
This method is recommended for pigs that are exposed to PCV2 before 7 weeks of age 
and offers optimal best immunity (Intervet). This method should be used if the co-
infection disease pressure is high. In addition, Merck has also implemented Circumvent 
PCV-M G2, which is currently the only 1-dose, single-bottle, combo vaccine for PCV2 
and mycoplasmal pneumonia (Merck). 
 Suvaxyn PCV2®One Dose is a killed-recombinant vector vaccine, which uses an 
inactivated PCV1-2 chimera antigen (Burch, 2008), to prevent PCV2 viremia and reduce 
PCV2 –associated lymphoid depletion. Recombinant vector vaccines are similar to 
subunit vector vaccines; however they use attenuated viruses or bacterium to introduce 
viral DNA to cells of the body. This vaccine is marketed by Fort Dodge® Animal Health 
and can be administered in one dose using 2 ml in healthy pigs 4 weeks or older which 
reduces the stress on the pig as well as reduce the labor/production costs (Burch, 2008). 
 Circovac® is produced by Merial, and is used for sows and gilts and to provide 
passive protection/immunity to offspring via colostrum. Production of the vaccine 
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involves an inactivated PCV2 virus to produce the antigenic component and mineral oil 
as the adjuvant. Sows vaccinated with Circovac®, experienced a reduction in PCV2 
circulation and shedding in piglets (Charreyre et al., 2005). In addition, these piglets 
demonstrated improved health during an experimental infection at 3-4 weeks of age 
(Charreyre et al., 2005). Although this vaccine is proven to be effective, it is also labor 
intensive because it requires two doses of 2 ml given 3 to 4 weeks apart before mating.  
In addition, this vaccine program requires a booster to be given every gestation period.  
 Several studies have been conducted to determine the effectiveness of various 
vaccines. A study conducted by Lyoo and others (2011) tested the effectiveness of 
Circumvent PCV ™, Ingelvac® CircoFLEX™, and Suvaxyn PCV2® One Dose. In this 
study, 4 pigs were randomly selected per 20 different litters (n=80). Of the 4 pigs per 
litter, 3 were randomly assigned vaccines and 1 was designated as a control. Vaccines 
were administered via protocols directed from their respective companies. The three 
different vaccine groups fluctuated in average daily gain (ADG). Pigs that were given 
Circumvent PCV ™, and Ingelvac® CircoFLEX™ experienced higher overall ADG 
compared to the control pigs (P<0.05). Viremia was relatively low in the vaccinated pigs. 
For instance only 15.2 % of pigs given Suvaxyn PCV2® One Dose, 16.9% of pigs given 
Circumvent PCV ™, and 18.1% of pigs given Ingelvac® CircoFLEX™ tested positive 
for PCV2 DNA, compared to 27.5% observed in controls.  Although PCV2 DNA was 
detected in vaccinated animals, no clinical symptoms were observed.  
 Takahagi and others (2009) conducted a study to evaluate the effects of using two 
commercially available vaccines (Ingelvac® CircoFLEX™ and Porcilis® PCV) in 
Japanese commercial pig farms demonstrating PCV2 infections. A total of 997 pigs were 
55 
 
randomly selected and assigned to one of three groups: (i) Porcilis® PCV vaccinated 
group, (ii) Ingelvac® CircoFLEX™ vaccinated group, and (iii) a control group. At 24 
week, the mortality rate for the vaccinated pigs was 11% for the Porcilis® PCV 
vaccinated group, and 13% for the Ingelvac® CircoFLEX™ vaccinated group, compared 
to 32% observed in the control group.  The results of this study reveal that using 
Porcilis® PCV and Ingelvac® CircoFLEX™ resulted in a reduction in mortality. 
 Research has demonstrated that PCV2 vaccination can have a minimizing effect 
on ADG, mortality rates, as well as PCV2 viremia and shedding. This suggests that 
PCV2 vaccination is a practical possibility for reducing the PCVAD incidences and 
should be implemented into common swine management techniques. 
 
Genetic Parameters Used For Selection 
 Currently there is no prevention method that is entirely secure in protecting 
against PCV2 infections; however, recent research has suggested the potential to select 
animals that are less susceptible to PCV2 infections. Bates and others (2008) evaluated 
the genetic and environmental effects that influence variation in PCVAD. In this study, 
3,271 pigs from two genetic lines known for reproductive and growth traits were 
evaluated for PCVAD symptoms. Each pig was given a score from 0 to 2, based on 
PCVAD symptoms such as wasting, respiratory difficulty, decreased growth, and 
diarrhea. A score of 0 indicated no symptoms and signified that the pig was normal. A 
score of 1 denoted minor symptoms and indicated potential PCVAD progression. A score 
of 2 was given if the pig demonstrated obvious characteristic symptoms of PCV2 
infection. All pigs that were given a score of 2 were humanely euthanized and were 
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evaluated during necropsy. In addition, immunohistochemistry and real-time PCR was 
also performed for each evaluation. Of the 3,271 pigs, 41 experienced co-infections with 
M. hyopneumoniae (n=19), Streptococcus suis (n=18), and Lawsonia intracellularis 
(n=4).  
 The PCVAD scores for each pig were compared to birth weight, weaning weight, 
weight at d65, and weight at d180 to estimate correlations and heritabilities. Moderate 
correlations were found between PCVAD score and birth weight (r=0.34, P< 0.10) as 
well as PCVAD score and weight at d65 (r=-0.53, P< 0.01). Heritabilities were moderate 
for PCVAD score (0.16+/- 0.04), and weaning weight (0.16 +/- 0.06), birth weight (0.27 
+/- 0.07), and both weight at d65 and at d180 (0.23 +/-0.06). Heritability estimates were 
larger at d90 compared to d125 for viremia (0.38 +/- 0.11 vs. 0.11 +/- 0.08) and IgG 
antibody titres (0.55 +/- 0.21 vs. 0.10 +/- 0.08). 
 The results from this study suggest that immune response to PCV2 is heritable; 
therefore genetic selection in herds where PCV2 is prevalent could be a potential method 
to decrease PCV2 infections. Although PCV2 vaccinations have an effect on ADG, 
mortality rates, as well as PCV2 viremia and shedding, they increase production and 
labor costs. Selecting animals that appear to have less susceptibility to PCV2 could be a 
potential alternative to vaccinations and even be used as a complementary tool in cases 
where extra protection is needed. 
 
Summary  
 Porcine circovirus type 2 (PCV2) is the major causative agent responsible for 
inducing the development of PCVAD. In addition, PCV2 is an economically important 
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pathogen because it is environmentally stable and its infectious capability has the 
potential to infect large populations.  As the global population increases, the demand for 
meat also rises indicating a need for healthier pork production. Therefore, pigs with 
increased resistance to PCVAD and other diseases will play an essential role in the future 
of pork production worldwide. 
 Although the PCV2 pathology is not completely clear, vaccines have proven 
successful in the prevention of PCV2 outbreaks and have an effect on ADG, mortality 
rates, as well as PCV2 viremia and shedding. Previous research has demonstrated that 
breed differences influences susceptibility and plays a role in PCVAD progression, 
suggesting that genetic selection may be the next step for reducing the incidences of 
PCVAD. Selection based on DNA markers associated with PCVAD resistance has the 
potential to decrease economic losses, improve animal welfare and provide alternatives to 
vaccination. 
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CHAPTER 2: Phenotypic Variation of the Indicators of PCVAD Susceptibility in 
Experimental Infection with PCV2b 
 
 
2.1 INTRODUCTION 
 
 
 In order to improve productivity, economic efficiency and animal welfare in 
swine operations, proper control and prevention of infectious diseases is crucial. Porcine 
circovirus 2 (PCV2) has been identified as the etiological mediator responsible for 
stimulating the progression of a multifactorial disease known as porcine circoviruses 
associated diseases (PCVAD), which exhibits a variety of symptoms. PCVAD 
encompasses several diseases including post-weaning multisystemic wasting syndrome 
(PMWS), PCV2-associated enteritis, porcine respiratory disease complex (PRDC), 
PCV2-associated reproductive failure, and porcine dermatitis and nephropathy syndrome 
(PDNS). PCV2 is an economically important pathogen because its virulent aptitude has 
the capability of infecting large populations, which significantly impacts production 
efficiency of the global swine industry (Opriessnig et al., 2006). 
 PMWS appears to be the most frequently occurring PCV2-associated disease and 
is characterized by wasting in weaned pigs, dyspnea, diarrhea, and lymphoid depletion 
(Allan et al., 2000; Opriessnig et al., 2006). Swine operations suffering PMWS outbreaks 
typically experience high mortality. Pigs affected with PCV2-associated enteritis 
demonstrate diarrhea, decreased weight gains, and inflammation of the large intestine 
(Kim et al., 2004). Pigs affected with porcine respiratory disease complex (PRDC) show 
signs of decreased growth, low feed efficiency, anorexia, fever, cough, and dyspnea 
(Halbur, 1998b; Thacker, 2001). Sows suffering from PCV2-associated reproductive 
failure typically experience abortion, as well as increased delivery of stillbirths, and fetal 
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mummies (Kim et al., 2004; Gillespie et al., 2009). Porcine dermatitis and nephropathy 
syndrome (PDNS) involves the development of red and purple skin lesions on limbs and 
abdomen (Drolet et al., 1999; Harding, 2004) and typically affects nursery and grower 
pigs (Opriessnig et al., 2007). 
 Several studies have demonstrated that vaccinations are the most effective method 
of PCV2 prevention and control (Takahagi et al., 2009). In order to successfully reduce 
the effects on ADG, mortality rates, as well as PCV2 viremia and shedding, every pig in 
the system must be vaccinated. Swine operations that employ vaccinations into their 
herd-management program will experience a decrease in PCV2 infections; however, it 
increases production cost, especially when the number of vaccination solutions and novel 
pathogens continues to increase.  
 Previous research has suggested that Landrace pigs are more susceptible to 
PCVAD compared to other breeds such as Large White, Yorkshire, Duroc or Pietrain, 
which indicates that variation in host genetics plays a role in PCVAD susceptibility 
(Zhou et al., 2006; Opriessnig et al., 2006; Opriessnig et al., 2009). Therefore, using host 
genetics to select for PCVAD resistance in the nucleus population could be an alternative 
and/or complementary method to vaccination and have the potential to reduce production 
costs.  
 The following research investigates the phenotypic variation in response to 
experimental challenge with PCV2b in various crossbred populations. The data collected 
during the experimental challenge was used to evaluate the difference between individual 
responses to infection. The objective of this research was to assess phenotypic variation 
of important indicators of PCV2 susceptibility. Gaining a better understanding of the 
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immunosuppressive role of PCV2 and factors that influence the development of PCVAD 
will provide essential information regarding the swine immune system, benefiting the 
global swine industry. 
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2.2 MATERIALS AND METHODS 
 
 
 
Experimental Design: Animals, Diets, and Housing 
 The experimental procedures used during this study were reviewed and approved 
by the Institutional Animal Care and Use Committee of the University of Nebraska-
Lincoln (UNL). The pigs used for the experimental challenge were distributed over time 
in nine batches (B1 to B9) ranging from 81 to 141 pigs per batch. Barrows were used in 
all of the batches except B2 and B3, which consisted of both barrows and gilts.  
 A total of 974 experimental pigs produced from 320 litters with 3.04 pigs per 
litter were provided from two resources including the UNL Swine Research Unit, and 
members of the PigGen Canada Consortium. The UNL Swine Research Unit produced 
maternal and terminal crossbred pigs for batches 1 through 4 (n=386) and members of the 
PigGen Canada Consortium provided maternal crossbred pigs for batches 5 through 9 
(n=588). The structure of the resource population can be seen in Table 1.  
 The pigs produced by The UNL Swine Research Unit involved three major breeds 
including Large White, Landrace, and Duroc of commercial origin as well as the 
Nebraska Index Line, which has been selected since 1981 mainly for traits related to litter 
size. The pigs provided by members of the PigGen Canada Consortium involved two 
major breeds including Large White (dams), and Landrace (sires). Further description of 
the breeding systems for each resource batch can be seen in Table 2. 
 All experimental pigs were colostrum fed and raised under similar conditions. 
Before experimental infections, each pig was evaluated and tested negative for the 
presence of PCV2. Furthermore, each pig was also tested for levels of IgG and IgM 
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PCV2 specific antibodies. Pigs used for the experimental infection had to show a 
sample/positive ratio (S/P) lower than 0.3 for passive IgG maternal antibodies and lower 
than 0.4 for IgM (McKnite et al., 2014). This was an essential aspect of the selection 
process because the S/P thresholds were used to assess the level of IgG maternal 
antibodies (passive) as well as determine if pigs were actively infected (IgM) or had 
experienced previous PCV2 exposure (host IgG). High levels of passive antibodies were 
associated with reduced susceptibility to PCVAD (McKeown et al., 2005). Any pig that 
demonstrated S/P threshold values that exceeded the limit was culled from the selection 
pool. Pigs that demonstrated negligible S/P levels and tested negative for PCV2 were 
transferred to the UNL Animal Science Complex for the experimental challenge. 
 Throughout the experimental infection, pigs were housed in one experimental 
room containing 24 identical pens. Pigs were randomly assigned to a pen, which 
consisted of both slatted and solid surface flooring. Each pen provided approximately 
0.65 square meters of floor space per pig. The diet used involved a standard balanced diet 
that met or exceeded nutritional requirements (NRC, 1998) and was fed ad libitum. Upon 
arrival at UNL facilities, each pig received a preventative dose of 0.8 ml of Baytril® 100 
for any unaccounted bacterial pathogens. 
   
PCV2b Isolate and Experimental Infection 
 The PCV2b strain used for the experimental infection was isolated from a pig 
with characteristic PCV2 symptoms. The sequence of the experimental strain belongs to 
the PCV2b cluster from Quebec (Canada) and is highly similar to strain FMV-05-6507, 
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which is known to induce clinical signs of PMWS as well as produce high mortality rates.  
The strain was cultured in swine testicular lines as described in McKnite et al. (2014). 
 Experimental pigs were inoculated with a titer of 10
4.0
 TCID50/ml of the PCV2b 
strain both intranasally and intramuscularly. The average age of infection across all 
batches was 43 days of age. Daily observations were conducted during the 28-day 
experimental period to monitor and detect clinical symptoms. In addition, weight and 
blood samples were collected a 0, 7, 14, 21, and 28 days post infection (dpi). 
 
PCV2 Sequencing 
 PCV2b viral isolation was performed using QIAamp DNBA Minikit (Qiagen). 
Two primer sets including Forward 1: GCAGCACCTCAGCAGCAA, Reverse 1: 
TCCTCCGTGGATTGTTCTGTAGC, Forward 2: TTTTGCAGACCCGGAAACCA, 
and Reverse 2: CAGCGCACTTCTTTCGTTTTCA along with Go Taq Flexi DNA 
Polymerase (Promega) were used for amplifying the viral genome. After amplification, 
the PCR products were then purified using ExoSAP-IT (USB Corporation). The 
experimental strain was sequenced from both directions using dye terminators using ABI 
PRISM 3100 Genetic Analyzer (Applied Biosystems) and aligned to PCV2 DNA 
sequences available in GenBank using ClustalW2 (Larkin et al., 2007). In addition, after 
the experimental challenge, random viral DNA samples from all batches were amplified 
and sequenced under the same procedures to validate the PCV2 strain of the PCV2b 
strain used for experimental infection. 
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Serology 
 Blood samples were collected in sterile 7 ml Monoject Red Stopper Blood 
Collection Tubes containing no additives (item # 8881301413 Tiger Medical, Irvington, 
NJ, USA). The blood was then equally separated into 7.5 ml BD Vacutainer tubes 
(Reference # 367987, Franklin Lakes, New Jersey, USA) and 7.5 ml Tempus Blood RNA 
tubes (Reference # 4342792 Life Technologies, Carlsbad, California). The tempus blood 
RNA collection tubes contain a RNA stabilizing solution (Applied Biosystems Carlsbad, 
California, USA). Once all of the blood samples were collected, the tempus blood RNA 
collection tubes were placed in a -20°C freezer for storage and the BD Vacutainer tubes 
were immediately centrifuged at 3500 rotations per minute (rpm) for 15 minutes at 4°C. 
After centrifugation, the serum was poured into a 2.0 ml tube and placed in a -20°C 
freezer for storage.  
 
PCV2 Specific Antibodies  
 Enzyme-linked immunosorbent assay (ELISA)(Ingenasa, Madrid, Spain) was 
used to evaluate the levels of PCV2 specific antibodies such as IgG and IgM in serum. 
Samples exhibiting a S/P ratios greater than 0.4 were considered to be positive for IgG, 
and S/P ratios greater than 0.3 were considered to be positive for IgM. The levels of 
PCV2 specific antibodies were normalized based on positive control values. 
 
Viral DNA Quantification 
 Viremia or estimates of viral copy counts in blood were also measured for each 
pig. Viral DNA was first isolated from serum samples using QIAamp DNA Minikits 
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(Qiagen, Valencia, California, USA) and was then quantified by conducting quantitative 
real-time PCR (qPCR) using TaqMan Master Mix and ABI 7900 Real Time PCR System 
(Applied biosystems). Area under the curve (AUC) was used to evaluate the total viral 
load for each pig throughout the entire experimental challenge period. Viral load was 
calculated for each pig using an algorithm based on viremia levels determined at each 
time point (0, 7, 14, 21, and 28 dpi) to fit a smooth curve over the 28 day infection period 
and summed the areas in increments of 0.01 time units (Boddicker et al., 2012).  
 
DNA Isolation and Genotyping 
 Ear notch samples were taken from each pig for DNA isolation. DNeasy or 
Puregene tissue kits (Qiagen, Valencia, California, USA) were used for the DNA 
extraction. DNA extracts were assessed using a NanoDrop Spectrophotometer (Thermo 
Scientific, Wilmington, Delaware, USA) as well as agarose gel electrophoresis for DNA 
quantity and quality. DNA extracts were used for genotyping as described in chapter 3. 
  
Statistical Analysis 
 Pair-wise correlations between residuals were estimated based on a linear mixed 
model treating batch as a fixed effect, age at infection and passive IgG levels as 
covariates, as well as litter and pen as random effects. The means and measures of 
variability were estimated for each trait across time points, as seen in Table 3. 
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2.3 RESULTS AND DISCUSSION 
 
 
 
Immune Response in Growing Pigs 
 Although PCV2 is classified as a pluripotent virus, it predominately replicates in 
epithelial and endothelial cells (Steiner et al., 2008). PCV2 also inhibits the function of 
Natural Interferon Producing Cells (NIPC) also known as plasmacytoid dendritic cells 
(pDC), which play a critical role in the innate immune response. These NIPC/pDC are 
associated with the secretion of several pro-inflammatory and anti-viral cytokines 
including tumor necrosis factor-α (TNFα), and type I Interferons, (IFNs), which are 
involved with anti-viral immunity. PCV2 inhibits the function of NIPC/pDC by 
preventing the stimulation of interferon- α (IFNα) and TNFα involved in the maturation 
of myeloid dendritic cells, which secrete interleukin 12 (IL-12) to assist with T cell 
differentiation. The process of T cell differentiation is crucial for anti-viral immunity and 
recognition of bacterial and viral pathogens. Inhibition of this process leads to secondary 
infections (Vincent et al., 2005) and can severely impact growth performance. Therefore, 
swine operations use vaccines to decrease the progression of PCVAD. Several studies 
have provided substantial evidence, indicating that the use of PCV2 vaccines is useful in 
controlling the development of PCVAD (Horlen et al., 2008; Fachinger et al., 2008; 
Kixmoller et al., 2008; Opriessnig et al., 2009; Neumann et al., 2009). 
 
Growth Rate During Experimental Infection with PCV2b 
 The viral strain used for the experimental infections was isolated from a pig 
demonstrating characteristic signs of PCVAD and similar in DNA sequence to a 
83 
 
Canadian cluster of strains known to induce PCVAD and increase mortality rates (e.g., 
FMV-05-6507)(Gagnon et al., 2007; Carmen et al., 2008). Differences in PCV2 virulence 
in both experimental and natural infection have been demonstrated in previous research 
(Opriessnig et al., 2006; Opriessnig et al., 2008). 
 Differences in ADG between weeks following experimental infection showed a 
decrease in rate of ADG occurred during the third week, compared to the other weeks. 
The mean weekly ADG can be seen in the Figure 1. The most variation observed in ADG 
occurred between 21 (x   0.48, σ = 0.25), and 28 dpi (x   0. 8, σ = 0.28). The results of 
this analysis can be seen in Table 3. 
 
Real-time PCV2 Quantification 
 Blood samples were collected throughout the challenge at 0, 7, 14, 21, and 28 dpi 
and evaluated for the levels of circulating virus. Real-time quantitative PCR was used to 
measure the number of viral copy counts in each experimental pig. The levels of 
circulating virus began to increase at day 7, and peaked at day 14, followed by a decline. 
The results of this analysis can be seen in Figure 2. The immune response patterns 
observed during this challenge were similar to the results in other studies (Pensaert et al., 
2004; Opriessnig et al., 2004; Opriessnig et al., 2006). The most variation observed in 
weekly viremia measures occurred at 14 dpi (x    3.64, σ = 1.24). In addition, the 
variation for viral load was high (x   68.8, σ = 24.7). The results of this analysis can be 
seen in Table 3. 
 Pair-wise correlations of residuals were conducted between viremia measures and 
average daily gain during (ADG) infection. Moderate negative correlations were 
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observed between viremia at 14, 21, and 28 dpi and ADG from 14-21, 21-28, and 0-28 
dpi (r= -0.30 to-0.39; P < 0.001). The largest estimate between weekly viremia measures 
and ADG was detected between viremia at day 21 and ADG between days 14-21 (r=-
0.39, P<0.001). The results of this analysis can be seen in Table 4. In addition, a 
moderate negative correlation was detected between viral load and overall ADG (r=-0.36, 
P<0.001). The results of this analysis can also be seen in Table 4.  In addition, the largest 
estimate for viral load was detected at ADG from 21-28 dpi (r=0.39, P<0.001). No 
significant relationships were detected between ADG prior to infection with viremia 
during the first two weeks of the challenge (r= 0.01 to 0.03, P> 0.63) or viral load (r= -
0.02, P= 0.73) (McKnite et al., 2014).  This indicates that there is a negative correlation 
between viral load and ADG, which can be seen in Figure 3. Therefore viremia and viral 
load are the best predictors for ADG decline following infection. 
  Slow growth may be a consequence of an animal’s inability to clear the virus as a 
result of a weak immune system, which increases the possibility of acquiring a secondary 
infection. A study conducted by Meerts and others (2005) indicated that levels of PCV2 
viremia influenced susceptibility to post-weaning multisystemic wasting syndrome 
(PMWS) in both natural and experimental PCV2 infections.  In this study, animals with 
high viremia had increased susceptibility where animals with less viremia were not as 
vulnerable. 
 
Variation in Immune Response in PCV2b-Challenged Pigs  
 Prior to experimental infection, all pigs demonstrated a S/P less than 0.4 for IgG, 
less than 0.3 for IgM, and negative to PCV2, which indicates no current or previous 
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PCV2 exposure or PCV2 vaccination, indicating that all pigs were PCV2 negative. The 
levels of PCV2 specific antibodies were normalized based on positive control values.  
 Previous reports indicate that most PCV2 infected pigs demonstrate subclinical 
symptoms in both natural and experimental infections because antibodies produced by 
the humoral immune response and other unexplained mechanisms are able to clear the 
virus (Meerts et al., 2005). Of the antibody isotypes (IgA, IgD, IgE, IgG, and IgM), IgG 
and IgM are responsible for the main anti-viral immunity against invading pathogens. 
IgG is secreted as a monomer and is the only antibody capable of crossing the placenta, 
providing passive immunity from the dam to the fetus (Pier et al., 2004). Colostrum 
contains high levels of IgG and IgA to provide immediate immunity to offspring. IgG 
responds later to the site of infection, but is the primary antibody associated with anti-
viral immunity against invading pathogens (Pier et al., 2004). IgM functions in two 
forms. It can either be expressed on the surface of B cells in a monomeric form or 
secreted in a pentameric form. IgM is produced immediately after exposure and 
eradicates any invading pathogens in the initial stages of humoral immune response 
before necessary levels of IgG are produced (Pier et al., 2004). IgM has very high avidity 
and indicates acute infections. 
 IgG and IgM levels were comparable with previous studies across the measured 
time points 0, 7, 14, 21, and 28 dpi (Opriessnig et al., 2006; Opriessnig et al., 2008), and 
can be seen in Figure 4. IgM levels were detectable before IgG, which was expected, 
again confirming that none of the experimental pigs had been previously exposed to 
PCV2. The variation in IgM immune response appeared in two main groups: early 
responders and late responders, delayed by one week approximately. IgM titres in early 
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responders began to increase at 7 dpi, and peaked at 14 dpi followed by a waning period. 
In the late responders, IgM titres began to increase at 14 dpi, and peaked at 21 dpi 
followed by slow declining titres. IgM antibody response for each pig can be seen in 
Figure 5. 
 IgG titres started to increase in most experimental pigs at 14 dpi, peaking between 
21 and 28 dpi. IgG antibody response for each pig can be seen in Figure 6. 
 IgG is primarily associated with the neutralizing capacity (r= 0.85, P< 0.001) (Fort et al., 
2007); therefore high titres of IgG indicate exposure to PCV2. In a study conducted by 
Meerts and others, decreased levels of neutralizing antibodies resulted in an increase in 
PCV2 viral replication and progression of PMWS (Meerts et al., 2006). 
 The most variation observed in antibody titres occurred at 28 dpi for IgG (x    
2.23, σ = 0.95) and 21 dpi for IgM (x   1.64, σ = 0.68). The results of this analysis can be 
seen in Table 3. 
 The results from the analysis of IgG and IgM titres across time points 
demonstrates that immune response varies in the magnitude and in the induction of the 
humoral response to PCV2b in experimental pigs. The variations followed a similar trend 
in viremia. 
 Pair-wise correlations between IgG/IgM and average daily gain (ADG) were 
relatively low and are listed in Table 5. In addition, moderate pair-wise correlations were 
observed between IgG at 21 and 28 dpi and overall viremia (0-28 dpi) (r= 0.026 to 0.27; 
P < 0.0001 ) as well as between IgM at 21 and 28 dpi and overall viremia (0-28 dpi) (r= 
0.32; P < 0.0001 ).  These correlations are listed in Table 6. 
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 All pigs receiving colostrum obtain antibodies that provide early immunity 
against PCV2 and other pathogens. The effectiveness is dependent upon the rate at of 
antibody decline, which typically occurs between 5-18 weeks (Opriessnig et al., 2009). 
Previous studies have demonstrated an association between titres of passive (maternal) 
IgG antibodies and the extent of protection against PCV2 (McKeown et al., 2005). For 
instance, low IgG titres are associated with an increased number of PCV2 positive pigs, 
where high IgG titres are associated with lower numbers of PCV2 positive pigs. 
Understanding the influence of PCV2 specific antibodies on disease progression may 
eventually become a trait used by producers for genetic selection of PCV2 resistant pigs. 
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2.4 CONCLUSIONS 
 
 
 
 There are numerous challenges in developing management programs to prevent 
PCV2 infections. Because the virus is exceptionally stable, disinfecting is difficult.  In 
addition, PCV2 is present worldwide, and nearly every swine operation in the United 
States has already been exposed to the virus. The fact that PCV2 is extremely stable and 
is present globally creates opportunities for viral transmission, making it challenging to 
produce specific-pathogen-free animals. The use of vaccines has proven successful; 
however, every pig in the swine system needs to be vaccinated for efficient protection, 
which significantly increases the cost of production. In addition, every pig needs to be 
closely monitored for signs of infection, which can be problematic because many infected 
pigs experience subclinical infections and do not express visible symptoms. Therefore 
routine antibody profiling using diagnostic tests such as ELISA are required to detect 
PCV2 infections, which also increases production cost due to labor as well as increases 
stress to the animals. 
 These results based on experimental infection with PCV2b determined a 
substantial variation in the initiation and magnitude of both viremia as well as the 
humoral immune response based on IgG and IgM antibody titres across all batches of 
pigs. The mechanism of how certain pigs inhibit viral replication is not well understood, 
and further research is needed to gain a better understanding of the role of host genetics 
in response to infection. 
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CHAPTER 3: Genomic Analysis of The Main Indicators of Susceptibility 
 
3.1 INTRODUCTION 
 
 
 
 Genetic selection has been used to improve production efficiency in the swine 
industry for many years. The main traits used in swine selection were carcass traits, such 
as back fat, and loin eye area, performance traits including average daily gain, feed 
efficiency, and days to 120kg, as well as reproductive traits including number born alive, 
number weaned, litter size, and reproductive longevity (Tart et al., 2013). 
 The United States is one of the world’s most predominant pork producing 
countries, ranking second in the quantity of pork products imported and exported. As the 
global population increases, the demand for pork rises, indicating a need for improved 
production efficiency (USDA). Therefore using genetic selection to improved production 
performance will become an essential method for meeting consumer demands. 
Traditional selection traits are useful for improving production efficiency in healthy pigs; 
however, pathogen exposure is one the main factors preventing swine operations from 
experiencing the full benefit of genetic gains. In this study, the difference in phenotype 
expression in experimental challenge with a viral pathogen between experimental pigs of 
different origin emphasizes the role of host genetics in disease susceptibility. For 
example, potential genetic differences across experimental animals at loci involved in 
immune response could suggest that certain pigs were more capable of inhibiting viral 
replication, whereas others were not as effective at combating the infection. For this 
reason, selection for pigs with reduced susceptibility to pathogenic exposure could be a 
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practical method for improving disease resistance, and has been suggested for developing 
increased PCVAD resistance in pigs (Bates et al., 2008). 
 In order to effectively select animals with reduced pathogenic vulnerability, a 
panel of reliable DNA markers is crucial to predict individual immune response. 
Conducing experimental infections using infectious porcine pathogens is required to 
identify associated DNA markers to be used for assembly of this panel. 
 The objective of the present study was to identify genetic variants and genes that 
impact individual immune response and influence PCVAD susceptibility. In this study, 
various crossbred lines were challenged with a PCV2b strain similar to a cluster of 
PCV2b strains known to induce clinical signs of PCVAD and increase mortality rates. 
Viremia, immune response and ADG were measured weekly; all animals were genotyped 
with a 60K SNP panel and genome-wide association analyses were employed. This study 
provides the baseline for analyzing genomic indicators of PCV2 susceptibility.  
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3.2 MATERIALS AND METHODS 
 
 
 
Genotyping 
 
 Ear notch samples were taken from each experimental pig for DNA isolation and 
genotyping. DNA was extracted using either DNeasy or Puregene blood and tissue kit 
(Qiagen). DNA products were evaluated for quantity and quality using NanoDrop 
Spectrophotometer (Thermo Scientific) and agarose gel electrophoresis. 
 Each experimental pig was genotyped using the first or second generation Porcine 
SNP60K BeadArray (Illumina, San Diego, California), which included 62,183 SNPs for 
the first generation and 61,565 SNPs for the second generation. Of the common SNPs, 
91.6% (61,177) were mapped to the reference sequence for the porcine genome using 
Build 10.2. To remove low quality DNA samples and SNP assays, a minimum GenCall 
genotype quality score of 0.40 and a genotyping call rate of 0.80 were used (Tart et al., 
2013). Therefore, the genome-wide association analyses included 56,433 SNPs to profile 
each of the 974 experimental pigs. 
 
Sequence Analysis 
 DQB1 and DRB1, candidate genes located in the SLA II region were amplified 
using genomic DNA from selected animals for high and low viral load using Go Taq 
Flexi DNA Polymerase (Promega) and sequenced using dye terminators and ABI PRISM 
3100 Genetic Analyzer (Applied Biosystems). DNA sequences were aligned using 
Sequencher (Gene Codes) software for polymorphism discovery. 
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Statistical Analysis 
 The GenSel software package (Fernando and Garrick, 2008) was used to estimate 
the proportion of phenotypic variance for ADG, immune response and viremia explained 
by high-density SNP genotypes using a Bayes B model (Kizilkaya et al., 2010). The 
model used for this analysis included litter, pen, and batch as fixed effects and were 
designated as class variables. In addition, the levels of passive IgG and age at infection, 
which were considered to be covariates.   
 A genome-wide association study utilizing 56,433 SNPs was preformed using a 
Bayes B model (Kizilkaya et al., 2010) with pen, batch and litter as class variables, and 
passive IgG titers at day 0 and age at infection as covariates. The model included a π 
value of 0.99 assuming that 99% of the SNPs have no effect on the phenotypic variance 
and was run for 41,000 iterations, discarding the first 1,000 samples as burn in. In 
addition, the effects from every 40
th
 iteration were used to produce the posterior 
distribution for the genetic variance, which was used to determine the probability of each 
window having an effect greater than 0 or having an effect greater than the average 1 Mb 
window (Tart et al., 2013). Genetic and residual variances were estimated and modified 
based on similar literature results because sire effects were not included in the model. 
Individual genotypes and SNP effects were used to estimate genomic prediction values as 
described by Fernando and Garrick (2008). 
 Individual genotypes and SNP effects were used to estimate genomic prediction 
values for each pig as described by Fernando and Garrick (2008). Comparing pair-wise 
correlations of genomic prediction values across traits was used for the evaluation of 
potential common sources of variation. 
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 In addition, single-marker associations between genotypes of a subset of SNPs 
and phenotypic traits were evaluated using JMP 10.0 (SAS Inst. Inc.) and a linear mixed 
model treating batch and SNP genotype as fixed effects, age at infection and passive IgG 
titres at day 0 as covariates, as well as litter and pen as random effects. The effect of the 
number of favorable alleles was estimated with a linear mixed model treating batch and 
the number of favorable alleles across two SNPs as fixed, age at infection and passive 
IgG titres at day 0 as covariates, and both litter and pen as random effects. 
 
Gene Ontology/ Positional Candidate Gene Approach 
 The 1 Mb windows associated with the most significant differences in viral load 
and ADG were extended by 1 Mb in both directions to further distinguish possible 
candidate sources. Build 10.2 Sus scrofa assembly and Ensembl Genes 70 database and 
BioMart data-mining platform (http://uswest.ensembl.org/biomart/martview) were used 
to uncover possible swine candidate genes based on human orthologs.  
 The development of gene ontology terms (GO BP FAT) and pathway analysis 
based on human orthologs was performed using DAVID (http://david.abcc.ncifcrf.gov/), 
to further characterize possible candidate sources. 
The ontology terms include 3 domains such as cellular component, biological process, 
and molecular function. The cellular component refers to the location in a cell or the 
extracellular environment where the gene product is active. The biological process refers 
to the molecular events affected by the gene product and the relevance to the functioning 
of cells, tissues, organs, and organisms. The molecular function, describes the 
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biochemical activities of a gene product such as enzyme, transporter, and ligand (The 
Gene Ontology Consortium et al., 2000). 
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3.3 RESULTS AND DISCUSSION 
 
 
 
 
Proportion of Phenotypic Variance Explained By SNPs 
 In general, an increase in viremia and immune response was characterized not 
only by an increase in phenotypic variation but also by an increase in the proportion of 
the phenotypic variation explained by SNPs. The proportion of phenotypic variance 
explained by SNP genotypes for viremia measurements expressed moderate percentages 
ranging from 19%, detected at 7 dpi to 52%, detected at 14 dpi. In addition, 64 % of the 
variation for viral load over 0-28 dpi was explained by 60K genotypes as seen in Table 7. 
The proportion of the variance observed in IgM immune response explained by SNP 
variants ranged from 14% detected at 7 dpi to 60% detected at 14 dpi, while IgG immune 
response ranged from 3% detected at 7dpi to 44% dpi detected at 21 dpi. The impact of 
the SNP genotypes on the variation in ADG was generally weak ranging from 7% 
detected between days 14 – 21 and 21-28 dpi, to 13% detected between 0 – 7 dpi. The 
overall proportion of variance for ADG was 16%. 
 
 PCV2 Viremia: The results from conducting a genome-wide association study 
(GWAS) using a Bayes B model revealed two major SNPs, ALGA0110477 and 
ALGA0039710, which explained 11.5% and 2.8% of the genetic variation for viral load as 
seen in Figure 7. The location of ALGA0110477 is positioned at the proximal end of 
SSC12 at 3.66 Mb based on linkage disequilibrium estimates (r > 0.32 with SNP 
ALGA0122316). The location of ALGA0039710 is positioned within a region of the swine 
genome known as the Swine Leukocyte Antigen II  (SLA II) complex, which is one of 
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the most gene-dense regions in the swine genome involved in immune response (Lunney 
et al., 2009). Genes located in this region are important determinants in immune response 
to pathogens (Lunney et al., 2009). The SLA complex is highly polymorphic and consists 
of three major clusters (class I, II, and III) that span chromosome 7. The coding regions 
of two of the genes located in the SLA II region, DQB1 and DRB1 were sequenced in 
experimental pigs selected for both high and low levels of viral load.  
 By analyzing genetic variation explained by 1 Mb windows, we found that the 1 
Mb window located at the proximal end of SSC12 and the window located at SSC 7 
together explained 18.5% of the genetic variation. ALGA0110477 and ALGA0039710 
explained more than 94% of the genetic variance associated with their respective 
windows. The first ranked 1 Mb window containing ALGA0110477 is located at the 
proximal end of SSC12 and explains 10.5% of the additive genetic variance for viral 
load. The probability of the effect explained by this window being significantly greater 
than zero and also greater than the average genetic variance explained by the 1 Mb 
windows was greater than 0.99. The second ranked 1 Mb window containing 
ALGA0039710 is located on SSC7 and explains 7.7% of the additive genetic variance for 
viral load. The probability of the effect explained by this window having an effect greater 
than zero and greater than the average genetic variance explained by 1 Mb windows was 
greater than 0.90. 
 The proportion of phenotypic variance for weekly viremia explained by SNPs 
ranged between 19% to 52%, with the greatest contributions detected at 14 (52%) and 21 
dpi (45%) as seen in Table 7. The top windows for viremia at 14 dpi were located at SSC 
7 (25 Mb), SSC 7 (28 Mb) and SSC 7 (24 Mb) and explain approximately 10.99% of the 
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genetic variance. Analysis of single DNA marker effects showed that after the top 3 
SNPs located in the SLA I (ASGA0031928, SSC7, 25.1 Mb) and SLAII regions 
(INRA0024482, SSC7, 29.6 Mb; ALGA0039710, SSC7, 28.9 Mb) the forth SNP was 
ranked ALGA0110477 (SSC12), associated with the largest individual effect on viral 
load. The top windows for viremia at 21 dpi were located at SSC 7 (28 Mb), SSC 7 (29 
Mb) and SSC 6 (126 Mb) and explain approximately 12.97 % of the genetic variance. 
The windows located at 28, 29 Mb overlap SLA II complex of genes.  
 
 PCV2 IgM and IgG: The proportion of phenotypic variance for IgM explained 
by SNPs ranged between 14% to 60%, with the greatest contributions detected at 14 
(60%) and 21 dpi (44%) as seen in Table 7. The top windows for IgM at 14 dpi were 
located at SSC 19 (39 Mb), SSC 12 (3 Mb) and SSC 12 (31 Mb) and explained 
approximately 0.76 % of the genetic variance. The top windows for IgM at 21 dpi were 
located at SSC 5 (86 Mb), SSC 6 (9 Mb) SSC 14 (25 Mb) and explained approximately 
1.48 % of the genetic variance. The top windows for IgM at 28 dpi were located at SSC 
15 (151 Mb), SSC 1 (251 Mb) SSC 5 (87 Mb) and explain approximately 2.29 % of the 
genetic variance. 
 The proportion of phenotypic variance for IgG explained by SNPs ranged 
between 3% to 44%, with the greatest contributions detected at 21 (44%) and 28 (38%) 
dpi as seen in Table 7. The top windows for IgG at 21 dpi were located at SSC 11 (11 
Mb), SSC 4 (81 Mb) and SSC 8 (72 Mb) and explained approximately 1.35 % of the 
genetic variance. The top windows for IgG at 28 dpi were located at SSC 14 (135 Mb), 
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SSC 10 (59 Mb) and SSC 6 (119 Mb) and explained approximately 1.17 % of the genetic 
variance. 
 PCV2 Average Daily Gain: The proportion of phenotypic variance for weekly 
ADG explained by SNPs was limited ranging between 7% to 16%. The largest proportion 
of phenotypic variance for ADG was for overall ADG measured between 0 to 28 dpi and 
was 16% as seen in Table 7. The top windows for ADG between 0 and 28 dpi were 
located at SSC 1 (137 Mb), SSC 14 (31 Mb) and SSC 18 (3 Mb) and explain 
approximately 1.44 % of the genetic variance. 
 
Genetic Relationships Between Indicators of PCVAD Susceptibility 
 
 Correlations of genomic prediction values were conducted between weekly 
viremia and ADG measures during infection. Moderate correlations were observed 
between viremia measures at 21, and 28 dpi and ADG at 14, 21, and 28 dpi (r=- 0.11 to -
0.33, P< 0.001). The largest estimate was detected between viremia at 21 dpi and ADG 
between 14-21 dpi (r= -0.33). The results of this analysis indicate that viremia is the best 
predictor for ADG decline during experimental infection. The results can be seen in 
Table 8.  
 
SLAII Haplotypes 
  Sequencing analysis of DQB1 and DRB1 in individuals with extreme values for 
viral load showed SLAII haplotype distributions similar with those previously reported 
(Ho et al., 2010; https://www.ebi.ac.uk/ipd/mhc/sla).  For example, of the 10 haplotypes 
identified based on DQB1 sequences, haplotype 701 was the most frequent, and was 
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present in 28% of the selected animals. The haplotypes were constructed using 55 SNPs 
detected by sequencing of DQB1 comparing the haplotypes with the sequences available 
on Immuno Polymorphism Database (https://www.ebi.ac.uk/ipd/mhc/sla).   Of the 
animals selected for low viral load, haplotype 701 was the most frequent (36%). Of the 
animals selected for high viral load, haplotype 701 (20%) and 901 (20%) were the most 
common.  The observed haplotypes are listed in table 9. 
 
Pleiotropic Effect on Viremia, ADG, and Immune Response 
 Pair-wise correlations between genomic prediction values (GPV) generated from 
Bayesian analyses indicated that common loci potentially influence the variation across 
traits especially on viremia and ADG. The strongest correlations discovered occurred 
between viremia detected at 21 dpi and ADG between days 14–21 dpi, and 21-28, and 0-
28 dpi  (r = -0.27 to -0.33, P< 0.0001). 
 These relationships and potential pleiotropic loci that influence viremia, immune 
response and ADG were demonstrated by single-marker association studies for the SNPs 
that following Bayes analyses displayed the largest effects - ALGA0110477 and 
ALGA0039710. For example, the favorable genotype CC for ALGA0110477 was 
associated with the lowest viral load (58.6) and with the highest ADG (0.50 kg) 
compared to the CT (67.3, P< 0.0001; 0.47 kg, P< 0.05) and TT (74.0, P< 0.0001; 0.45 
kg, P< 0.001) genotypes. Experimental animals with the CC genotype also experienced 
lower IgM titres detected at day 14, 21, and 28 dpi as well as lower IgG titres detected at 
21 and 28 dpi compared to CT (P<0.05) and TT (P< 0.0001). These associations indicate 
that regions on SSC12 and SSC7 containing these DNA markers have an effect on the 
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relationship between viremia and ADG as well as between viremia and immune response. 
Within each experimental batch, the frequency for the favorable allele ranged from 0.36 
and 0.68. 
 
Effect of Favorable Alleles on Viremia, Immune Response, and ADG  
 The number of favorable alleles of the two SNPS located at SSC7 and SSC12 had 
a large impact on the levels of viremia, immune response, and growth. Animals that 
contained four favorable alleles experienced the lowest viremia levels, lowest levels of 
IgM and IgG, and the highest ADG, where animals with one favorable alleles 
demonstrated the highest viremia levels, highest IgM and IgG levels, and the lowest 
ADG. These results can be seen in Figures 8-11. These effects appear to be additive 
across the number of favorable classes.  
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3.4 CONCLUSIONS 
 
 
 
 The variance in phenotype expression between experimental pigs in this study 
implies the role of genetic components in disease susceptibility. Genetic differences 
between experimental animals indicates that certain pigs were more efficient in reducing 
viral replication, initiating an effective immune response and clearing the virus faster 
compared to others.  
 Using genome-wide association analyses to identify important genetic variants in 
experimentally infected pigs, a significant variation in host genetics involved in viremia, 
ADG, and immune response was discovered. Two major SNPs were identified that 
explain 11.5% (ALGA0110477) and 2.8% (ALGA0039710) of the genetic variation 
responsible for viral load. ALGA0110477 is located on the proximal end on SSC12 (3-4 
Mb) and ALGA0039710 is located within the SLA II region on SSC7 (28-29Mb). The 
results from this experimental infection indicate that these SNPs partially explain the 
variation in viremia, ADG, and immune response. In general, individuals that are 
observed homozygotes for the favorable alleles for ALGA0110477 and ALGA0039710 
experienced lower viral load and increased ADG than the other genotypes, indicating that 
these SNPs are closely linked to a functional loci with a role in immune response and 
reducing viral replication. 
 This study serves as the basis for future research involving the influence of host 
genetic variations on the immune response PCV2 and other pathogens. These DNA 
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markers can be used for the assembly of a panel of genetic markers used for genetic 
selection to efficiently select for individuals that are less susceptible to PCV2. 
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TABLES 
 
 
 
 
Table 1. Resource Population  
 
Batch Number of 
Animals 
Number of 
Litters 
Pigs Used Per 
Litter 
Source 
 
 
1 – 4 386 95 4.1 UNL Swine 
Research Unit 
 
5 - 9 588 225 2.6 PigGen Canada 
Consortium 
 
Total 
 
974 320 3.04  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    Table 2. Breeding systems for each resource batch. 
Batch Dam Sire Number of 
Litters 
Pigs 
Used/Litter 
Animals 
Infected 
 
1 Large White x 
Landrace 
 
Landrace 19 4.3 81 
2 Large White x 
Landrace 
 
Nebraska Index 
Line 
30 3.2 95 
3 Large White x 
Landrace 
 
Duroc 20 6.0 120 
4 Nebraska Index Line 
 
Landrace 26 3.5 90 
5 Large White 
 
Landrace 66 1.8 116 
6 Large White 
 
Landrace 30 3.0 89 
7 Large White 
 
Landrace 37 3.5 131 
8 Large White 
 
Landrace 57 2.5 141 
9 Large White 
 
Landrace 35 3.2 111 
Total  
 
 320 3.0 974 
1
0
9
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          Table 3. Variation Observed Across All Traits 
 
Trait Mean ± Standard Error Standard Deviation 
IgG d 0 0.78 ± 0.006 0.19 
IgG d 7 0.73 ± 0.005 0.15 
IgG d 14 0.83 ± 0.008 0.24 
IgG d 21 1.69 ± 0.028 0.86 
IgG d 28 2.23 ± 0.032 0.95 
IgM d 0 0.62 ± 0.005 0.15 
IgM d 7 0.68 ± 0.006 0.18 
IgM d 14 1.34 ± 0.020 0.61 
IgM d 21 1.64 ± 0.022 0.68 
IgM d 28 1.32 ± 0.020 0.59 
ADG 0-7 0.36 ± 0.007 0.22 
ADG 7-14 0.45 ± 0.007 0.22 
ADG 14-21 0.48 ± 0.008 0.25 
ADG 21-28 0.58 ± 0.009 0.28 
ADG 0-28 0.47 ± 0.006 0.19 
Viremia d 0 0.03 ± 0.006 0.18 
Viremia d 7 1.45 ± 0.039 1.20 
Viremia d 14 3.64 ± 0.040 1.24 
Viremia d 21 3.42 ± 0.041 1.26 
Viremia d 28 2.63 ± 0.041 1.25 
Viral Load 68.80 ± 0.810 24.69 
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Table 4. Pair-wise Correlations of Residuals Between Viremia and Average Daily Gain. 
 
 ADG d 0-7 ADG d 7-14 ADG d 14-21 ADG d 21-28 ADG d 0-28 
Viremia d 7 0.051 -0.081 -0.115 ** -0.068 -0.074 
Viremia d 14 -0.016 -0.109 ** -0.316 ** -0.322 ** -0.290 ** 
Viremia d 21 -0.036 -0.177 ** -0.389 ** -0.384 ** -0.371 ** 
Viremia d 28 -0.016 -0.104 * -0.308 ** -0.376 ** -0.334 ** 
 
 
 ADG d 0-7 ADG d 7-14 ADG d 14-21 ADG d 21-28 ADG d 0-28 
Viral Load 0.007 -0.139 ** -0.337 ** -0.387 ** -0.356 ** 
 
 
* P= 0.01 
 
** P= 0.001 
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Table 5. Pair-wise Correlations of Residuals Between IgG/IgM and Average Daily Gain. 
 
 ADG d 0-7 ADG d 7-14 ADG d 14-
21 
ADG d 21-
28 
ADG d 0-28 
IgG d 7 -0.009 -0.006 0.007 0.048 0.024 
IgG d 14 0.010 0.052 0.114 ** 0.092 ** 0.108 ** 
IgG d 21 0.034 0.076 * 0.025 -0.023 0.018 
IgG d 28 0.013 0.018 0.026 -0.020 0.009 
 
 
 ADG d 0-7 ADG d 7-14 ADG d 14-
21 
ADG d 21-
28 
ADG d 0-28 
IgM d 7 -0.014 0.004 0.045 0.046 0.046 
IgM d 14 0.074 0.038 -0.041 -0.090 * -0.044 
IgM d 21 0.024 0.046 -0.010 -0.047 -0.021 
IgM d 28 0.040 -0.045 -0.109 * 0.144 ** -0.118 ** 
 
 
* P= 0.01 
 
** P= 0.001 
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Table 6. Pair-wise Correlations of Residuals Between Antibody titres and Viremia. 
 
 
 Viremia d 7 Viremia d 14 Viremia d 21 Viremia d 28 Viral Load 
IgG d 7 -0.043 -0.059 -0.037 -0.058 -0.066 
IgG d 14 0.118 ** -0.123 ** -0.142 ** -0.109 ** -0.080 
IgG d 21 0.206 ** 0.252 ** 0.092 * 0.075 0.260 ** 
IgG d 28 0.165 ** 0.312 ** 0.181 ** 0.061 0.270 ** 
 
 Viremia d 7 Viremia d 14 Viremia d 21 Viremia d 28 Viral Load 
IgM d 7 0.112 ** 0.020 0.027 0.012 0.066 
IgM d 14 0.281 ** 0.245 ** 0.127 ** 0.153 ** 0.312 ** 
IgM d 21 0.114 ** 0.329 ** 0.191 ** 0.175 ** 0.317 ** 
IgM d 28 0.082 0.330 ** 0.274 ** 0.159 ** 0.316 ** 
 
 
 
* P= 0.01 
 
** P= 0.001 
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           Table 7. Proportion of Phenotypic Variance Explained By 56,433 SNPs 
 
 7 14 21 28 
Viremia 0.19 0.52 0.45 0.39 
IgM 0.14 0.60 0.44 0.52 
IgG 0.03 0.08 0.44 0.38 
 
 
Trait/ dpi 0-28 
Viral Load 0.64 
 
 
Trait/ dpi 0-7 7-14 14-21 21-28 0-28 
ADG 0.13 0.11 0.07 0.07 0.16 
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Table 8. Relationships between Genomic prediction values for indicators of PCVAD 
Susceptibility  
 
 ADG d 0-7 ADG d 7-14 ADG d 14-21 ADG d 21-28 ADG d 0-28 
Viremia d 7 0.175 ** -0.015 0.045 0.104 * 0.081 
Viremia d 14 -0.017 -0.070 -0.082 0.038 -0.050 
Viremia d 21 -0.086 * -0.176 ** -0.328 ** -0.274 ** -0.300 ** 
Viremia d 28 -0.052 -0.109 ** -0.269 ** -0.169 ** -0.218 ** 
Viral Load -0.049 -0.157 ** -0.178 ** -0.210 ** -0.247 ** 
 
 
* P= 0.01 
 
** P= 0.001 
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Table 9. SLA II Haplotypes in Animals Selected for Low and High Viral Load 
 
Haplotype Number of Animals Haplotype Frequency 
Low High Low High Whole Data Set 
101 1 2 0.04 0.08 0.06 
201 1 4 0.04 0.16 0.09 
303 4 2 0.14 0.08 0.11 
402 1 0 0.04 0.00 0.02 
501 6 0 0.21 0.00 0.11 
601 5 3 0.18 0.12 0.15 
701 10 5 0.36 0.20 0.28 
801 0 2 0.00 0.08 0.04 
901 0 5 0.00 0.20 0.09 
40101 0 2 0.00 0.08 0.04 
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FIGURES 
 
 
 
 
Figure 1. Average daily gain (ADG) following experimental infection with PCV2b. 
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Figure 2. Variation in viremia following PCV2b experimental infection. 
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Figure 3. Association Between Overall Average Daily Gain (0-28 dpi) and Viral Load 
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Figure 4. Variation in Immune Response Following PCV2b Experimental Infection IgM 
titres shown in blue; IgG titres shown in red.  
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Figure 5. Individual immune based on IgM after PCV2b experimental infection. 
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Figure 6. Individual immune based on IgG after PCV2b experimental infection. 
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Figure 7. Genome-wide Association Analysis Between and Viral Load Following 
PCV2b Experimental Infection. 
 
 
 
 
Manhattan plot for viral load. The X-axis represents the Sus scrofa genome, where each 
color represents a different chromosome starting with chromosome 1 (SSC1) and ending 
with unmarked SNPs. The Y-axis represents the proportion of genetic variance explained 
each individual SNP. 
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Figure 8. The Number of Favorable Alleles for Viremia 
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Figure 9. The Number of Favorable Alleles for IgM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
 
 
 
 
Figure 10. The Number of Favorable Alleles for IgG 
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Figure 11. The Number of Favorable Alleles for ADG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
128 
 
APPENDIX 
 
 
Bayesian Analysis WinQTL Output Files: 
The following data represents output files from GenSel software used for genome-wide 
association study using a Bayesian B approach. These output files represent 
approximately 1 Mb windows, which are ranked based off of their genetic variance; 
therefore the top windows have the most genetic variation.  
 
 
Columns of Importance for Window Output File:  
Window- the Sus scrofa genome is broken up into 1 Mb windows along the genome 
#SNPs- the number of SNPs present in the window 
%Var- the percentage of the phenotypic variation represented by the particular window 
map_pos0- the chromosome and Mb that the window starts on 
map_posn- the chromosome and Mb that the window ends on 
 
 
Top Windows For Viremia 14 dpi 
 
 
 
Top Windows For Viremia 21 dpi 
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Top Windows For Viral Load 
 
 
 
 
Top Windows For IgM 14 dpi 
 
 
 
 
Top Windows For IgM 21 dpi 
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Top Windows For IgM 28 dpi 
 
 
 
 
Top Windows For IgG d 21 
 
 
 
 
Top Windows For IgG d 28 
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Top Windows For ADG 0-28 dpi 
 
 
 
